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Chapter I - Introduction 
~ Historic overview 
The role of the pituitary ghnd as being responsible for "the hormone char 
accelerates skeletal growth", or the "hormone of growth" was first 
acknowledged by Harvey Cushing ( 1;2]. Acromegaly is a rare disease due to 
prolonged hypersecretion of growth hormone (GHJ. In virrually all cases of 
acromegaly the cause is a benign GH-secrcting piruitary adenoma. In 1909 
Cushing reported that the clinical symptoms of acromegaly remitted after 
partial hypophysectomy thus pointing to the piruirary as playing a central 
role in the cause of acromegaly (3;4]. He also recognized the general role that 
the piruirary gland has in the regulation of the endocrine system and 
posrulated that certain diseases could be explained bypiruirary hypo- or 
hyperfunction(1]. Evans and Long confirmed the pituitary source of 
acromegaly when intraperitoneal injcaion of anterior pituitary extractS in 
rats resulted in acromegaly (5 ]. Later it was demonstrated char these 
piruirary extracts increased tibial epiphyseal width, which chen could be 
used as a bioassay ( 6;7]. After Raben succeeded in isolating GH ( 8], and a 
radioimmunoassay for GH was developed it turned out that GH conccnaa-
tions were indeed elevated in patients with acromegaly (9-n]. 
In 1953 the growth promoting effect of piruitary extracts was found to be 
related to sulphate incorporation into cartilage ( 12]. However, in subsequent 
experiments it became clear that in vitro GH could not stimulate the 
incorporation oflabeled sulphate into cartilage ftom hypophysectomized 
rats; whereas, serum ftom rats could ( 13 ]. Apparently the growth promoting 
effects ofGH were mediated through a "sulphation fuctor" present in serum. 
Interestingly, sera from patients with acromegaly contained elevated levels 
of this so called "sulphation fuctor" ( 14]. 
In 1963 Froesch era!. described char only a fraction of the insulin-like activity 
of normal serum could be blocked by the addition of anti-insulin anti-
bodies (15 ]. The term "non-suppressible insulin-like activity" was coined ( 15 ]. 
Dulak and Temin described another fuctor called "multiplication-stimulat-
ing activity" which has mitogenic activity ( 16]. In 1972 "sulphation fuctor", 
"non-suppressible insulin-like activity" and "multiplicarion-srimularing 
activity" were grouped together and named somatomedin ( 17]. Later 
Rinderknecht and Humble isolated two active somatomedins from human 
plasma and demonstrated a striking resemblance to proinsulin ( 18;19 ]. 
Accordingly the somatomedins were renamed Insulin-like growth factors. 
9 
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~ Growth honnone regulation 
10 
Two hypothalamic hormones, GH-rcleasing hormone (GHRH), and 
somatostatin (SRIF) are key regnlators of GH secretion. GHRH stimulates 
GH secretion whereas somatostatin inhibits GH secretion ( 20-22) (Fignre r). 
GHRP's I Ghrelin 
?t~ 
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Fi3ure 1: Overview of the r~ularion of the GH-IGF-I axis. 
Only very recently a third player in the field ofGH regulation has been 
identified: the growth hormone secreragogne ( GHS) system and especially 
ghrelin ( z3;24). Considering the fucr that in several of the studies described 
in this thesis ghrelin and one of its synthetic analogs (Growth Hormone 
Releasing Peptide-6) play an important role these compounds will be 
discussed in a separate section (vide infra). 
Introduction I Growth hormone resulation 
GH stimulates the production ofinsulin-like growth G.ctor-I (IGF-I) in the 
liver and local tissues (25). In addition to the stimulation of IGF-I synthesis 
GH also promotes the formation of the ternary IGF binding complex, 
including IGF binding prorein3 (IGFBP3) and acid-labile-subunit (AIS) 
(vide infra), which stabilizes IGF-I in serum (25). 
A role for IGF-1 in the regulation of GH was suggested by inrracercbrovcn-
tricular injection ofiGF-preparations in rats, which markedly diminished 
the amplitude of the observed GH pulses (26). However, these early 
preparations might have contained both IGF-I and IGF-II as in more recent 
experiments a combination ofborh recombinant human IGF-I and IGF-II 
was required to reproduce these observations (2p8). Further evidence for a 
role of!GF-I in the negative feedback regulation ofGH secretion was 
gathered from several in vitro experiments in which IGF-I decreases GH 
secretion and rnRNA levels in cultured rat pituitary cells (29;30 ). Moreover, 
even GH-sccrcting piruirary adenomas appear sensitive to the negative 
feedback exerted by IGF-I.I.amberts cr a!. demonstrated that during a 
24-hour incubation IGF-I directly inhibits GH release in four of seven 
primary rumor cell cultures prepared from somarotroph adenomas (31). 
IGF-I in serum is bound to several binding proteins: the so-called 
Insulin-like growth-factor binding proteins (IGFBP' s). To dare six IGFBP' s 
have been identified (32;33). All IGFBP' shave a high degree of sequence 
homology and are termed IGFBP 1 to 6 in the order in which their primary 
structure was unraveled (32;34). These circulating IGFBP' s acr as carrier 
proteins, transporting IGF to target tissues and prolonging the half-life of 
IGF by protecting them from proteolytic degradation ( 2 5). In addition to 
their major roles in circulation, most target tissues also express IGFBP' s. 
These IGFBP's further regulate actions of!GF at the tissue level (25;34). 
IGFBP-3 is the predominant binding protein in human serum (35). Afrer 
binding!GF-I, these rwo couple with AlS and thus a ternary complex is 
formed that is rhe main storage form of!GF-I in circulation. In humans both 
IGFBP3 andAIS arc GH dependent (35). Approximately 75-95% of total IGF-I 
is present in the ternary complex (35;36). 
IGFBP1 was first identified and purified from amniotic fluid (37). IGFBP1 has 
been proposed as an acute regulator of!GF-I activity and insulin seems to be 
a major regulator of!GFBP1 production (33:38;39). Most studies arc 
consistent with an inhibitory action ofiGFBP1 on IGF-I production in 
certain cell systems. However, IGFBP1 potentiates IGF-I effcets possibly 
through binding of!GFBP1 itself to the cell membrane (32;39-41). The role of 
11 
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the other IGFBP' s in IGF-1 action is less well established and will not be dis-
cussed here. 
- Growth Hormone Releasing Peptides and ghrelin 
12 
Since 1976 Bowers era!. and other groups have developed a series of pcpridcs 
derived from mer-enkephaline with powerful GH-releasing capacities. These 
pcprides arc called GH-ReleasingPeprides (GHRP's) (42-44). Moreover, in 
order to develop an orally active GH-secretagogue (GHS) several groups have 
developed non-peptidyl analogues of these GHRP' s of which MK-0677 is 
probably the most studied compcund to dare (45'.46). The GHRP's probably 
exert their GH-releasing action through a GHS-receptor (GHS-R) expressed 
in hypothalamus and pituitary (45). 
All GHRP' s exert a direct GH releasing effecr on the pituitary, as they are 
capable to stimulate GH release from somatotrophs cultured in vitro (45). 
However, in vivo GH release- is exerted via a hypothalamic pathway. 
After administration of a specific antagonist to GHRH in healthy men, GH 
response to GHRP-6is eliminated (47). Moreover, in patients with a 
hypothalamo-pituitary disconnection GHRP' s do not induce GH release (48). 
Finally, the combined administration ofGHRH and a GHS has profound 
synergy (43;49). 
Only very recendy a natural ligand for the GHS-Ru has been identified and 
calledghrelin (23). Surprisingly the highest concentration of ghrelin was 
found in the mucosa of the stomach and nor in the hyporhal=us or 
pituitary gland ( 23). Unique is the posttrauslational addition of a n-octanoyl 
group covalendy linked to the hydroxyl group of serine on position three via 
an ester linkage (5o;51). The n-ocranoyl group adds a hydrophobic property 
to theN terminus dur may facilitate entry and distribution in the brain (5o). 
Non-octanoylared (des-acyl) ghrelin is biologically inactive and has no GH 
releasing capacity ( 23;50 ). 
The GHS-R was characterized using a radio labeled synthetic GHS (MK-o677). 
Subsequendy it was shown that GHRP-6 comperirively inhibits binding of 
MK-0677 to the GHS-R (45). Also, the sigrul trausduction pathways for 
MK-o677 and GHRP-6 both involve phospholipase C, resulting in a rise in 
inositol triphosphate and intracellular calcium (45). Afi:er identification of 
this GHS-R, a cell line expressing this receptor was developed and used to 
identity tissue extracts that conld stimulate the GHS-R as monitored by 
increases in intracellular Ca2+ (24). By adding different tissue extracts to this 
cell line and monitor intracellular Ca2+ changes, Kojima eta!. isolated 
Introduction I Growth Hormone Rdeasi"B Peprides andghrdin 
ghrelin from rat and humansromach [23). Therefore we can conclude that 
GHRP-6 andghrelin bind to the same GHS-R that is responsible for GH 
release. 
Intravenous ghrelin administration stimuhtes GH secretion [52-57). 
Interestingly, apart from this effect on GH secretion, a metabolic action 
of ghrelin can also be recognized. In animal studies peripheral ghrclin 
administration stimulates food intake, gastric secretion, gastric motility and 
obesity [58-65). TschOp er al. have recendy described that ghrelin induces 
obesity in rodents [58). Dutingperipheral[subcutaneousJ ghrclin 
administration once a day to mice for 2 weeks, body weight and far mass 
increased without changes in food intake, locomotor activity, lean body 
mass, or bone mass [58). Because ghrclin releases GH, and GH is lipolytic 
rather than lipogenic [vide infra), these findings indicate that other 
mechanisms that lead to obesity are stimuhred as well. 
w+wllii!i!iih Relationships between GH and lit mass 
Observations in acromegalic patients as well as studies on body composition 
in GH deficient [GHDJ patients before and during GH rcphcement indicate 
that GHD affects body composition in man [ 66-68]. Already in 1934 it was 
reported that administration ofGH to experimental animals led to a reduc-
tion in fur mass [ 69 ]. In subsequent years indirect evidence- by measuring 
free furry acids [FFA)- became available that in man GH also mobilizes far 
stores [7o-72). Finally, these observations were confrrrned by measuring body 
compositions in patients with disturbances in the GH-IGF-I axis [ 67;68]. 
In acromegalic patients body composition is characterized by an increase in 
lean body cell mass, a reduction in fat mass and "overhydration" of the body 
due to an increase in extracellular water [ 68;73-75). Prolonged untreated 
GHD is associated with an increase in fur mass as well as an abnormal fur 
distribution [ 67,68;)'6;77]. In GHD patients body fur mass was approximately 
6-8 kg higher compared ro controls [ 67;68;)'8]. Moreover, GH replacement 
therapy leads to a decrease in fur mass in GHD patients [ 66;68]. Based on 
these data it can be concluded that GH is an active player in the regulation 
ofbody composition. However, the opposite is also true: GH levels arc also 
influenced by body composition as well as by nutritional status. 
In fasting and other catabolic states IGF-1 levels are decreased despite 
elevated GH concentrations [22). Apparendy in these situations subjects lack 
the ability to produce an adequate IGF-I response to GH. Recent studies 
suggest that portal vein insulinopcnia contributes to the observed "GH 
13 
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resistance" in catabolism. In such a mechanism down-regulation ofheparic 
GH receptor expression secondary to porul vein insulin deficiency could 
explain the apparent GH resistance observed in this disease ( 22;:79). The 
observed decrease in cirrulati.ng concentrations ofGH Binding Protein 
(GHBP), a putative index ofGH receptor number, in patients with type I 
diabetes mellitus (characterized by impaired insulin secretion) is consistent 
with this hypothesis (So). 
In obesity both basal and stimulated GH release is attenuated ( 22;81-86). The 
mediators of the regulation exerted by the adipose tissue on the GHjiGF-I 
axis are not fully understood yet, but in rhe last few years two relevant 
factors have emerged -FFA and rhe hormone leptin produced by adipocyrcs 
(22;87). FFA and GH integrate in a classical feedback loop whereby a rise in 
FFA- as a result of the previously discussed lipolytic cffecr ofGH- blocks GH 
secretion (87). This action is rapid, dose-related and cxerrcd at the pituitary 
level with no evident hypothalamic participation (87). A pharmacological 
reduction in FFA enhances GH secretion and eliminates the attenuation of 
GH release that is observed in obesity and Cushing's syndrome (87-89 J. 
Another mechanism by which adipose tissue participates in the regulation of 
GH secretion is lcptin [9o ). Obesity is associated with elevated levels of serum 
leprin while malnutrition and fasting arc associated with decreased lcprin 
levels (87). Indeed, visceral &t mass as estimated by computed tomography 
scanning is the primary (negative) statistical determinant of GH secretion in 
middle-aged men and women and accounts for both gender and age 
dependent differences in GH secretion (84]. In fasted rats, the pattern of GH 
pulsatiliryis eliminated with a ncar absence of spontaneous peaks, but the 
inrraccrcbrovcnrricular administration ofleptin restores the altered pattern. 
On the other hand in fed tats injected inttaccrebrovencriculat with 
antilcprin antibodies the normal GH secretory pattern is reversed to an 
absence of pulses, similar to the fasting state (87). Lcprin seems to have no 
direct pituitary action and its action at the hypothalamic level appears to be 
mediated by ncuropcptidc Y, being an important modulator of the 
somatostarinergic tonus (9rJ. 
In conclusion, relevant data indicate that GH and adipose tissue have cross-
talk mechanisms. However, at present it is unclear how to conceptualize 
the role ofGH in the regulation and distribution of fat mass in man. 
Fortunately, recent research in this field- most notably the discovery and 
description of ghcclin and its physiological role- has generated the potential 
for new insights in the relationship between GH and f.:tt mass [58;65 J. 
Introduction/ Pesvisomant 
!&--'"~~ ':& Pegvisomant 
In all studies described in this thesis the GH receptor (GHR) antagonist 
pegvisomanr played an important role. In the next section the mode of 
action and some clinical data will therefore be presented. 
Pegvisomant is a generically manipulated GH molecule that disables signal 
transduction through rhe GHR and thus functions as a GHR antagonist (9z). 
The GHR is a transmembrane receptor and consists of an intracellular and 
an extracellular domain linked by a transmembrane domain of 20- 30 amino 
acids (93). The extracellular domain of the GHR is also present in serum 
where ir acts as a GHBP (94). Binding ofGH to the GHR is necessary for 
signal transduction. It has been shown that dimerization ofGH with two 
GHR"s is critical for signal transduction to occur (95-97). GH has two distinct 
binding domains that bind to two identical GHR' sat the cell surface. 
Following the initial- high affinity- binding of the so called GH binding 
sire I at the GHR, sequential binding at GH site II produces functional 
receptor dimerization and signal transduction for example leading to IGF-I 
CH 
a 
-~blndlnr.· 
""'~ 
b 
CH 
(tlm('t1Z;><Jon.und 
"J:Tl<ll tn>n>du<t>On 
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.. ··\. 
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Fisure 2.: Mode of action of pesvisomanr: (a) normally GH binds to rhejirst GHR with 
bindins sire I; (b) the subsequent bindins ofbindins sire II to the second GHR results 
in receptor dimerization andsisnal transduction; (c) 8 mutations at bindins sire I 
increase the affiniry of pesvisomanr for the GHR and 1 mutation at bindins site II 
inhibits receptor dimcrization and rhus sisna! transduction. Adapted from Muller AF. 
Janssen]AMJL, de Herderww, van derLely A]. Growth hormone receptorantasonists: 
potentia[ indications. Ned Tijdschr Geneeskd zoo1; 145 (z):69-73· 
generation [Figure 2a & b J. The importance of receptor dimcrizarion in signal 
transduction is indicated by a number of experiments. High concentrations 
of GH, which favor the monomeric GH-GHR complex, inhibit rhe GH signal 
(98). Truncated receptors lacking the cytoplasmic domain act as dominant 
15 
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negative inhibitors of signaling by hetcrodimerization with the full-length 
receptor [99 ). Mutations in the interreceptor dimerization domain inhibit 
signaling without influencing GH binding ( 100 ). Finally, the strongest 
evidence comes from work with a GH molecule mutated at site 2 to prevent 
receptor dimerization [98;101-104). These GH mutants block GH-stimulated 
cell proliferation, the conformational change associated with receptor 
dimerization, and Jak-Stat signaling ( 1opo6). 
The understanding of the mechanism by which GH interacts with irs 
receptor has facilitated the development of pegvisomant (Figure 2c). 
Through a single mutation at site II of the GH molecule functional GHR 
dimcrization is inhibited. Moreover, to increase the binding affinity of the 
GHR antagonist and thus provide the GHR antagonist with a (pharmaco) 
kinetic advantage compared to endogenous GH, 8 amino acids at binding 
site I were also mutated (98;ror;107]. Pcgvisomant is pegylated to increase 
serum half-life time and to reduce the likelihood of antibody formation. 
Although the unpegylated GHR antagonist does have a higher affinity at 
site I of the GH, compared with endogenous GH, one must conclude that the 
pegylation process has major influences on this affinity, because in normal 
subjects high concentrations of pegvisomant (up to zooo-fold that of 
endogenous GH) are required to suppress IGF-I production (108). In 
acromegaly daily doses that are 20-40 times the daily dose for replacement 
purposes ofGH are required to control the disease. Indeed, recently it has 
been shown that pegylation reduces affinity of unpegylated pegvisomant for 
the GHR, an etfecr that is tar greater at the cell surface than for GHBP ( 100 ). 
These results provide an explanation for the high blood concentration of 
pegvisomant required to suppress IGF-I levels in normal subjects and in 
acromegaly. 
In a phase I, placebo-controlled, single rising-dose study in 36 normal young 
men it was shown that a single injection of pegvisorn.ant 1.0 mg/kg, reduced 
insulin-like growth ftcror-I by 49 ± 6% afi:er 5 days of" treatment" 
(P < o.oo1 vs. placebo) ( 109). The efficacy of pegvisomant in the treatment of 
acromegaly has been studied in a 12-week, double blind, placebo-controlled 
study. In this study 112 patients where treated with pegvisomant or placebo. 
Compared to baseline serum IGF-I levels were reduced significantly in a dose 
dependent fashion in all patients assigned to active treatment ( 110 ). Taken 
together it can be concluded that pegvisomant effectively blocks the GHR. 
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Chapter 2 - Aims and Outline of the thesis 
- Aims of the thesis 
The aim of the studies presented in this thesis was: 
a) to invesrigate the effects of GHR blockade- by using the GHR antagonist 
pcgvisomant - and fasting either alone or in combination on 
determinants of GH release; 
b J to invesrigare the effect of GHR blockade on cardiovascnlar risk markers 
in healthy non-obese males. 
- Outline of the thesis 
This thesis consists of three parts: 
In part I (chapter 3) we have invesrigared the effects of GHR blockade and 
fasting either alone or in combination on some known determinants of GH 
release. We have specifically invesrigated the putarive role of ghrelin in the 
mechanism whereby fasting leads to an increase in GH release. 
Then we describe and discnss the results of a study invesrigaring the effects 
of GHR blockade and &.sring either alone or in combinarion on GHRH and 
GHRP-6 srimulared GH release. 
Finally, in the last study of pan I we describe some GH independent 
metabolic effects ofGHRP-6. 
In parr II (thapter 4) we studied whether GHR blockade- as a model ofGH 
deficiency but without the cypical alterarions in body composirion-
influences insulin sensitivity, hemostasis parameters and serum lipid 
conccnrrarions in healthy non-obese males. 
Furthermore, we describe the case of an acromegalic subject that benefited 
from co-treatment with ocrrcotidc and the GHR antagonist pcgvisomanr. 
In part III (chapter 5) we discnss the main findings and hypothesize on 
possible clinical significance and potencial future developments. 
Finally, the summary- both in English and in Dutch - is presented in 
chapter 6. 
ZJ 
Chapter 3.1 - Ghrelin Drives Growth Hormone 
Secretion during Fasting In Man 
d Mtl\MI Abstract 
Alex F. Muller', Steven W.J. Lamberts', JoopA.M.J.L. Janssen', Leo 
J. Hofland', Peter van Koetsveld', Martin Bidlingmaier', Christian 
J. Strasburger', Ezio Ghigo', and Aarr Jan van der Lcly' 
In humans, fasting leads to elevated serum growth hormone (GH) 
concentrations. Traditionally, changes in hypothalamic Growth Hormone 
Releasing Hormone and Somatostatin release arc considered as the main 
mechanisms chat induce this elevated GH secretion during tasting. Ghrelin 
is an endogenous ligand of the Growth Hormone Secretagogue Receptor and 
is synthesized in rhe stomach. As ghrclin administration in man stimulates 
GH release, while serum ghrelin concenrrations arc elevated during fasting 
in man, this increase in ghrelin levels might be another mechanism whereby 
tasting results in stimulation ofGH release. Here we show that while 
ghre!in levels do not vary considerably in the fed state, fasting rapidly 
induces a diurnal rhythm in ghrelin concentrations. These changes in serum 
ghrclin concentrations during fasting were followed by similar, profound 
changes in serum GH levels. The rapid development of a diurnal ghrclin 
rhythm could not be explained by changes in insulin, glucose, or free larry 
acid levels. These clara indicate that ghrelin is the main driving force behind 
the enhanced GH secretion during fasting. 
<Ai•''"'4h Introduction 
zS 
In humans tasting enhances growth hormone ( GH) secretion and amplifies 
GH rhythm (r). Traditionally hypothalamic Growth Hormone Releasing 
Hormone and somatostatin release are considered as the mechanisms 
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whereby somatotroph output is regulated (a). Ghrelin, is an endogenous 
ligand of the Growth Hormone Secretagogue receptor (GHS-R) and was 
recently isolated from tat and human stomach, where it is synthesized in a 
distinct endocrine cell type (3:4). The gene for ghrelin encodes a 117 
aminoacid ptepto-ghrelin and is expressed not only in the stomach but also 
in the hypothalamic arcuate nucleus (4). Ghrelin exists in at least two forrus, 
an ocranoylated and a non-ocranoylated form. At present only ocranoylated 
ghrelin is thought to be biologically active (5-7). Intravenous ghrclin 
administration stimulates GH secretion through the centrally located 
GHS-R (8-1o). Besides this effect on GH secretion a metabolic action of 
ghrelin is also recognized. In animal studies peripheral ghrelin 
administration al.so stimulates food intake, gastric secretion, gastric motility 
and adiposity ( 11-13). As ghrelin administration in man strongly stimulates 
GH release and- at least in animal studies - ghrclin concentrations are 
elevated during fasting an increase in ghrdin concentration is another 
potential mechanism whereby &sting can stimulate GH release (8;10;12;14) 
The GHS-R was characterized using a radio labeled synthetic GHS called 
MK-0677, and subsequently it was shown that the binding ofMK-0677 to the 
GHS-R could be competitively inhibited by Growth Hormone Releasing 
Peptide-6(GHRP-6) (15). Also, the signal transduction pathways for MK-o677 
and GHRP-6 both involve phospholipase C resulting in a rise in inositol 
triphosphate and intracellular calcium ( 15). Afrer identification of the GHS-R 
a cell line expressing the GHS-R was established and used to identity tissue 
extractS that could stimulate the GHS-R as monitored by increases in 
intracellular Ca2+ (7). By adding different tissue extractS to such a cell line 
and monitor intracellular Ca2+ changes Kojima et aL isolated ghrelin from 
rat and human stomach (4). Taken together we can conclude from these data 
that GHRP-6 and ghrelin bind to the same receptor. 
Pegvisomant is a mutated GH molcrulc that prevents funaional 
dimetiaation and subsequent activation of the GH receptor (16;17). In normal 
subjectS and patients with acromegaly pegvisomant effectively blocks GH 
action and induces a decrease in (free) Insulin-like growth factor-! (!GF-I) 
concentrations ( 18;19 ). 
In the present study we have investigated the possible role of ghrelin in the 
mechanism whereby fasting leads to somatotroph hyperactivity. Firstly, 
we investigated the cffccrs of fasting on GH and ghrclin concentrations. 
Secondly, in order to investigate the possible role of some well-known 
metabolic substrates in the generation of the hypothesized diurnal ghrelin 
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rhythm, we also assessed insulin, glucose and free £my acid concentrations 
in serum. Thirdly, to determine the role ofGH and irs effects via the GH 
receptor in the regulation of ghrelin secretion during fasting we investigated 
if pretreatment with the GH receptor antagonist pcgvisomant influenced 
the effect of fasting on GH and ghrelin levels. Finally, to determine whether 
an auto feedback system for ghrclin is operative, and if so to investigate the 
influence of fasting hereon we investigated the effect of an intravenous bolus 
ofGHRP-6(thar docs not cross-react with the ghrelin assay) on ghrclin 
levels. 
- Subjects and Methods 
30 
Ten healthy male subjects (mean± SD age, 23.4 ± 2.7 year; range, 20- 28) 
with a normal body weight (mean± SD BMI, 21.8 ± 1.8 kg(mz; range, 
19.7-25.8) were asked to participate. None of the subjects had a relevant 
medical history or used medication. The local ethical commitree approved 
the study and all subjects gave wtitren informed consent. 
We performed a double blind placebo controlled crossover srudy comparing 
fasting with and fasting without GH receptor blockade. Afi:er an overnight 
fast subjects were admitred to the Clinical Research Unit on day 1 at 7-30 AM. 
On day 1 and day 4 a GHRP-6 test was performed. At 6PM on day 1 either 
pegvisomant- So mg as a single subcutaneous injection- or placebo was 
administered. A dose of8o mgwas chosen, as this dose is capable to reduce 
the GH concentration-dependent serum IGF-1 levels significantly ( 18), even 
in acromegalic patients. From 12 PM on day 1 until the end of the study- on 
day 4 at 8 PM- subjects fasted. Blood was drawn daily at 8 AM, 4 PM and 12 
PM. Ghrelin levels were determined from all samples, GH, and free IGF-I 
levels were determined from the 8 AM samples. Between the study periods 
there was a wash our period of 3 to 7 weeks. GHRP-6 was administered 
intravenously as a bolus injection of 1 11g/kg. Blood samples were drawn 
15 minutes and immediately before, and 15, 30, 45, 60,75,90, 105 and 120 
minutes afi:cr GHRP-6 injection. GH levels were determined in all samples. 
Ghrelin levels were determined from the samples drawn immediately before 
and 15, 30, 6o and 90 minutes afi:er GHRP-6 injection. Identical looking vials 
with GH receptor-antagonist (Pegvisomanr (SomavcrrTM), and placebo were 
supplied by Sensus Drug Development Corporation, Austin, Texas 78701, 
USA. 
GH samples were measured in a two-site immunoassay that docs not 
cross-react with pegvisomant ( 18). The assay exhibits a lower detection limit 
Ghrelin Drives Growth Honnone Secretion durin& Fastins in Man/ Subjeru and Methods 
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of o.02flg/L GH, an upper end of the working range of 50 11g/L for 25 flg/L 
serum samples, and no cross-reaction with pegvisomant up to a 
concentration of so,ooo flg/L 
It should be noted that the GH values obtained with this method are 
approximately so% of those obtained by conventional RIA method. The 
inrer-assay coefficients of variation (CV) arq.r% aq.o f.Lg/L and 3.S% at 
20 flg/L. The intra-assay CVs arq4% at o.25 f.lg/L, 1.9% at 2.5 flg/L, and+s% at 
25 flg/L. Serum free IGF-I was determined wirh a commercially available 
immunoradiometric assay (Diagnostic System Laboratories, Webster, TX; 
inrra- and interassay CV 10-3 and w.fi respectively). Ghrelin was detected 
with a commercial radioimmunoassay (Phoenix Pharmaceuticals, Belmont, 
CA; intra- and inrerassay CV +5- 5-3% and9.0 -13.6% respectively) that uses 
125-I labeled bioactive ghrelin as a rracer molecule and a polyclonal antibody 
raised in rabbits against full-length octanoylared human ghrelin. This assay 
has no cross-reactiviry with other relevant molecules. Insulin was assessed 
with a radioimmunoassay (Mcdgenix Diagnostics, Brussels, Belgium; 
inrra- and intcrassay CV 13-7 and S.o% respectively). Glucose was assessed 
with an automatic hexokinase merhod (Roche, Almere, The Netherlands). 
Free furry acids were determined with an enzymatic colorimcrric method 
(Wako Chemicals GmbH, Neuss, Germany; inrra- and interassay CV 1.1 and 
4-1% respectively). 
Means were compared with the Wilcoxon signed ranks test. All P-values arc 
two-sided, P-values < o.o5 were considered significant. Area under the curve 
was t.alculated using the trapezoid rule. 
Fasting rapidly induced a diurnal ghrelin and GH rhythm (Figure raJ, that 
was not seen in the fed sratc (data not shown). We also assessed insulin, 
glucose and free fatty acids concentrations in serum. Figure 1 b shows that 
thar the gradual changes in serum insulin, glucose and free furry acid levels 
are not related in rime to the acute changes in systemic ghrclin and GH 
levels during fasting. 
Compared to fasting without pegvisomant, tasting with pcgvisomant did 
not change the ghrclin rhythm (Figure u). However, compared to &sting 
without the presence of pegvisomant, fasting in combination with 
pegvisomant resulted in higher GH concentrations on day 3 (from SAM on 
day 3 to SAM on day 4; p<o.os for difference in area under the curve) (Fignre 
2b ). In the &sting state, both in the absence and in the presence of 
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Fisure r: 
Ghrdin, GH, insulin, 8 lucose and free 
fatry arid concentrations durinsfastins 
and after a bolus injection of GHRP-6. 
A. Solid line,shrelin levels; dotted line, 
GH levels. B. Solid line, insulin levels; 
small dors,slucose levels; larse dors,free 
fatry arid levels. Symbols represent mean 
±S.E.M. 
Fisurez: 
Ghrdin, GH and free IGF-I 
concentrations durinsfastins and 
durinsfastins in the presence of the GH 
receptor antasonist peavisomant. 
Symbols represent mean± S.E.M. Solid 
line,fastins; dotted line,fastins in the 
presence of pesvisomant 
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pegvisomant, serum free IGF-I levels decreased significandy. However, no 
additional etfecr of the presence of a GH receptor antagonist was observed 
(Figure 2c J. 
In all subjecrs and under all conditions GHRP-6 administration resulted in a 
powerful GH release (Figure 3a). GHRP-6 administration had no acute 
moditjing etfecrs on ghrclin levels (Figure 3 b). However, on the third day of 
:&sting early morning GHRP-6 administration attenuated peak ghrelin 
levels in the afremoon (Figure raJ. 
A 
Acute GH andshre!in response after 
administration of 1~8fk8 GHRP-6 
inrravenousry. A. Solid line, GH response 
on the 3rd d<ry offastins; dotted line, 
GH response at baseline. B. Dotted lin~ 
Ghrdin response at baseline; solid line, 
Ghre!in response on the 3rd day of 
fastins. Symbols represent mean 
±S.E.M. 
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In the present srudy we show that tasting rapidly induces an acute and 
distinct diurnal rhythm in systemic ghrelin concentrations that is not 
present in the fed stare. These changes in serum ghrclin levels during fasting 
arc followed by similar changes in serum GH concentrations, indicating that 
ghrclin is the driving force of increased GH secretion during fasting. 
A£ ghrclin is mainly produced in a distinct endocrine cell of the stomach this 
implies that the stomach can exert a direct control over the anterior 
piruirary (3). 
In order to investigate the possible role of some well-known metabolic sub-
strates in the generation of this diurnal ghrelin rhythm, we also assessed 
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insulin, glucose and free fatty acid concentrations in serum. Figure 1b clearly 
shows that that the gradual changes in these metabolic substrates is not 
related in time to the acute changes in systemic ghrelin and GH levels 
during tasting. Therefore, the rapid appearance of the observed ghrelin 
rhythm cannot be explained by acute alterations in insulin, glucose or free 
furry acid levels. Interestingly, during fasting pancreatic polypeptide shows a 
similar diurnal rhythm as ghrelin does (zo ). This opens the possibility that 
pancreatic polypeptide is responsible for the appearance of a ghrelin rhythm 
Since basal pancreatic polypeptide levels are low in human obesity this could 
also explain why circulating ghrelin levels are decreased in human obesity 
( 21;22). 
Compared to tasting without pegvisomant, pretreatment with pegvisomant 
resulted in a higher GH output on day 3 (from SAM on day 3 to SAM on 
day 4). Apparently, the blockade of the GH receptor induced higher GH 
levels. Serum free IGF-1 levels decreased signiticanrly in the tasting state, 
this decline was, however, not influenced by the presence or absence of 
pegvisomant. Thus, disabling the GH-GH receptor signaling system leads to 
an increase in GH output while in this san1e period free IGF-1 levels did nor 
change. These data indicate that other factors than free IGF-1- that is 
considered the most inlportant GH dependent feedback factor on GH release 
( 23;24)- are responsible for the additional increase in serum GH levels during 
fasting in the presence of pcgvisomant. These chta can be taken to indicate 
an ultra-short feedback loop of GH on its own secretion. Moreover, from 
rhcse san1e data we can also conclude that GH docs nor exert feedback on the 
production of ghrelin. 
An intravenous bolus injection of GHRP-6 had no acute- i.e. within 
90 minutes- effect on ghrelin levels. However, on srudy day four- the third 
day of fasting- early morning GHRP-6 administration attenuated peak 
ghrelin levels in the afternoon. Therefore, we postulate that ghrelin is- at 
least partially- regulated by a long loop negative auto feedback system. 
In conclusion, we have shown that &sting leads to a diurnal ghrelin rhythm 
that cannot be explained by changes in insulin, glucose, or free furry acid 
levels. These changes in serum ghrclin levels during fasting arc followed by 
similar changes in serum GH concentrations, indicating that ghrclin is the 
driving force of increased GH secretion during fasting. By using the GH 
receptor antagonist pcgvisomant we also provide indirect evidence that these 
changes in serum ghrelin levels are not regulated by che GH receptor. 
Finally, we found that the administration of the synthetic GH secretagogue 
Ghrdin Drives Growth Honnone Secretion during Fasting in Man /Discussion 
GHRP-6 was followed by a decrease of peak ghrclin levels, bur this effecr 
could only be observed after several hours, suggesting chat ghrelin 
concentrations are- ar least partially- regulated by a long-loop negative 
auto feedback control. 
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Chapter 3.2 -Effects ofFasting and Pegvisomant on 
the Growth-Hormone-Releasing-Hormone and 
Growth-Hormone-Releasing-Peptide-6 Stimulated 
Growth Hormone Secretion 
A.F. Muller M.D.', JAM.J.L. Janssen M.D.', S.W.J. Lamberts M.D.', 
M. Bidlingmaier M.D.', q. Strasburger M.D.', L. Hofland Ph.D.', 
A.J. vanderLclyM.D.' 
-Summary 
Pegvisomant is a mutated GH molecule which prevents functional 
dimerizarion and subsequent activation of the growth hormone receptor. 
Pegvisomant and tasting both lead to GH resistance. We performed a double 
blind placebo controlled cross-over study comparing the effects of 
pcgvisorn.ant and fasting on the growth hormone releasing hormone 
( GHRH) and growth hormone releasing peptide-6 ( GHRP-6) stimulated 
GH-relcase before anda.fi:er three days oftasring in ten healthy lean male 
subjects. We also performed a single arm open label study under non-tasting 
conditions in five of these subjects. On day one, in random order, at o8oo hrs 
a GHRP-6 or GHRH rest was performed. At r6oo hrs, a GHRH (if the first test 
was a GHRP-6 test) or GHRP-6 rest (if the first test was a GHRH test) was 
done. After the second test either pcgvisomant (So mg as a single 
subcutaneous injection) or placebo was administered. On day four, GHRP-6 
and GHRH tests were performed in the same order as on day one. During the 
cross-over study subjects tasted from 2400 hrs on day one until the end of the 
study. During the GH stimulation tests blood samples were drawn every 
15 minutes from-15 to 120 minutes. GH was determined in all samples. 
Total IGF-l and free IGF-I were determined from the samples at o minutes 
only. Three days oftasringalone and pegvisomant alone as well as in 
combination increased GH conccnrrarions whereas a decrease in serum free, 
but not coral, IGF-1 concentrations was observed. On day four, fasting and 
pegvisomant, either alone or in combination, significantly increased GH 
Department oflntcrrul. Medicine, Erasmus university Mediol Centre Rorrenbm, The Netherlands. 
2 DepJ.ttmcm oflmem:tl Medicine, Med Klinik InncnstJ.dt, Ludwig-Mx<imilians University, 80336" 
Munich, Germany, 
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concentrations after GHRH compared to baseline. Pegvisomant alone did not 
increase GH concentrations after GHRP-6 administration. Fasting alone 
increased GH levels ali:er GHRP-6 administration. The combination of 
fasting and pegvisomant had a synergistic effect on GH release afi:er GHRP-6. 
These human in-vivo data suggest that: 1. Circulating fi:ee IGF-I, and not 
total IGF-l, is the major component in the negative feedback on GH 
secretion; 2. Increased pituitary GHRH receptor expression plays a role in the 
mechanism whereby fasting leads to increased GH concentrations; 
3· In-vivo, GHRP-6 sensitivity seems to be primarily regulated by metabolic 
factors and not by changes in GH-IGF-I axis. 
- Introduction 
40 
Pegvisomant is a mutated growth hormone (GH) molecule which prevents 
functional dimerization and subsequent activation of the GH receptor ( 1 ), 
and is therefore a potencial new treatment for acromegaly (za). In nonnal 
subjecrs and patients with acromegaly pegvisomant effectively blocks GH 
action and induces a decrease in Insulin-like Growth Factor-! (IGF-I) 
concentrations. This decline in IGF-1 levels is associated with a concomitant 
rise in GH levels (4); in other words pegvisomant induces GH resistance. 
Fasting also leads to GH resistance which- at least in parr- can be explained 
by low portal vein levels of insulin insufficient to stimulate nonnal hepatic 
IGF-I synthesis (5;6). 
Growth Hormone Releasing Peptide-6 (GHRP-6) is a synthetic hcxapeptide 
that activates the GH secretagogue receptors in the hypothalamus and 
pituitary [7 ). An endogenous ligand for the GH secretagogue receptor, called 
ghrelin has recently been purified fi:om human stomach cxtracr (8). Besides 
Growth Hormone Releasing Hormone (GHRH) and somatostatin ghrelin 
could be another important factor in the regulation ofGH secretion (9;ro). 
Furthermore, relevant data indicate that GH sccretagogucs have an 
important- GH independent- role in metabolism ( n-13). 
In order to gain more insight in the stimulatory regulation of GH secretion 
under different metabolic conditions and the role of the GH receptor herein 
we pet:formed a double blind placebo controlled cross-over study comparing 
the effecrs of placebo with pegvisomant on GHRH and GHRP-6 stimulated 
GH-release both before and after tasting for three days. Additionally, we 
investigated the effecrs of pegvisomant on GHRH and GHRP-6 stimulated 
GH-rcleasc under non-fasting conditions. 
Effects ofFascin8 and Peavisomant on the Growth-Hormone-Re!easinB-Hormone and Growth-Hormone-
RdeasiJ18-Pepcide-6 Scimu!ared Growth Hormone Secretion I Subjects and methods 
- Subjects and methods 
Sru<!J; subjects 
Ten healthy male subjects (mean± SD age, 234 ± 2.7 year; range, 20- 28) 
with a normal body weight (mean± SD BMI, 21.8 ± 1.8 kg!m2; range, 
I9.7-25.8) were asked to participate. None of rhe subjects had a relevant 
medical history or used medication. All ten subjects participated in the 
cross-over study and five participated in the single-arm study. The study 
was approved by the local ethical committee and all subjects gave wcitten 
informed consent. 
E>:perimenral desi3n 
Two studies were performed (Fig. I): 
Fi3ure 1 
Cross-over study 
Pegvisomant (n = 5) fasting 
Placebo (n = 5) 
tasting 
Single arm study 
Pegvisomant {n = 5} 
non-fasting 
Genera! desi3n of the sru<!J;. 
Pegvlsomant 
fasting 
Placebo 
fasting 
I) A double blind placebo controlled cross-over study comparing 
pegvisomant with placebo before and after three days of fasting. 
2) A single arm open label study in which the effect of pegvisomanr under 
non-fasting conditions was investigated. 
Both studies lasted four days. All subjects were admitted to the Clinical 
Research Unit after an overnight fast. At admission rwo indwelling 
intravenous catheters were inserted. On day one, in random order, at 
o8oo hrs a GHRP-6 or GHRH test was performed. At I6oo hrs, a GHRH test (if 
a GHRP-6 test was performed in the morning) or a GHRP-6 test (if a GHRH 
rest was performed in the morning) was done. Between the tests a standard 
light meal was served. After the second test either pegvisomant (So mg as a 
4I 
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single subcutaneous injeccionJ or placebo was administered. This 
pegvisomanr dose has been shown to result in an effeccive blockade of the 
GH receptor. During the cross-over study sub jeers fasted from 2400 hrs on 
day one until the end of the study. On day four, GHRP-6 and GHRH rests 
were performed in the same order as on day one. In the single arm study all 
GHRP-6 tests were performed at o8oo hrs and all GHRH rests at 16oo hrs. 
GH-srimularion tests' 
GHRH (Ferring, Hoofddorp, The Netherlands] and GHRP-6 (Clinal&AG, 
Liiufdingen, Switzerland] were administered intravenously as a bolus 
injeccion of 1 [!g/kg. Blood samples were drawn every 15 minutes from-
15 to 120 minutes. GH was determined in all samples. Total IGF-I and free 
IGF-I were determined from samples at o minutes (T = o J ouly. 
Stucry medication 
Pegvisomant and placebo were supplied by Sensus Drug Development 
Corporation, Austin, Texas, USA 
Ass<rys 
All assays were done in duplicate. Setuni GH was determined with a 
previously described, non-commercially available two sire immunoassay 
that docs not cross react with pcgvisomant (intra-assay coefficients of 
variation (CVJ 3-4% at o.zwg/L, and +s% at zwg!L; inrerassay CV 4-1% at 
+o[!g/L, and 3.8% at zo[!g/LJ (4]. The absolute values for GH concentrations 
obtained by this assay are about so% of those provided by commercially 
available assays. Serum IGF-I was determined with a commerrially available 
radioinununoassay (Biosource Europe SA., Nivelles, Belgium; intra- and 
inrerassay CV 5.0 and9.6%, respeccivdyJ and free IGF-I was determined with 
a commercially available immunoradiomcrric assay [Diagnostic System 
Laboratories, Webster, Texas, USA; intra- and intcrassay CV 10.3 and ro.J'%, 
respeccivdyJ. 
Statistical anarysis 
All results are tepotred as mean± SEM Because all study periods were 
exactly the same untilr8oo hrs on day 1 and in order to minimize intra-
individual differences we used the means of the baseline values of the 
cross-over study as baseline values. Means were compared with the 
Wilcoxon signed rank test. Area under the curve (AUCJ was calculated by the 
Effects ofFasrins and Pesvisomant on the Growth-Honnone-Releasins-Honnone and Growth-Honnone-
ReleasinB-Pepride-6 Srimu!ated Growth Honnone Seaerion /Results 
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trapezoidal rule. Cotrelarions were calcuhted with pearson correlation 
coefficient. All p-values are rwo-sided, p-values <o.os were considered 
significant. 
GH stimufation tesrs 
Cross-over stu4Jt 
GHRH: Compared to baseline fasting alone and fasting in combination with 
pegvisomant significandy increased AUC afi:er GHRH [Fig. 2, upper panel). 
The effecr of fasting alone was not significandy different compared ro the 
effecr of fasting in combination with pcgvisomanr. 
GHRP-6: Fasting alone increased GH release afi:cr GHRP-6 administration 
[Fig. 2, lower panel). Fasting in combination with pegvisomant had a 
syncrgisric effccr on GH release afi:er GHRP-6. Compared to fasting alone 
fasting in combination with pegvisomant had a significantly larger effect on 
AUC afi:cr GHRP-6. 
Sin3le ann study 
GHRH & GHRP-6: Pcgvisomant alone increased AUC afi:cr GHRH bur not 
afi:er GHRP-6 administration [Fig. 2). 
:r:1 ~ 
~:~j~ 
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1500 
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Mean ( ± SEM) GHRH [upper panel) and GHRP-6 Uower panel) srimu!ared GH 
release [~s/LJ and area underrhe curve (AUC; ~8/Lfzh) at baseline [ • ), after 
pe3visomant [ o ), after fasrinB ( Ll) or after pe3visomant in combinarion with fasrin8 (L:). 
"'p<o.os, "'p<o.ot compared to baseline (Wi!coxonsi3ned rank test). 
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Cross over study vs sina!e ann study 
GHRH: Compared to pegvisomant alone fasting alone and fasting in 
combination with pegvisomant had similar effects on AUC afi:er GHRH. 
GHRP-6: The effect of fasting in combination with pegvisomant on AUC 
afi:er GHRP-6 was significantly larger than the effect of pegvisomant alone 
onAUC afi:er GHRP-6. 
Non-scimulared early momina GH and IGF-I levels 
Cross over study: Fasting alone non significantly increased GH levels (Fig. 3a). 
Three days of fasting combined with pegvisomant resulted in a significant 
increase in GH levels. Serum total IGF-1 levels did not change (Fig. 3b ). 
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Fasting alone resulted in significandy smaller changes in GH and total IGF-I 
concentrations chan &sting combined with pegvisomant. Three days of 
&sting alone as well as &sting in combination with pegvisomant decreased 
serum free IGF-I levels (Fig. 3c). The effects of &sting alone and &sting in 
combination with pcgvisomant on free IGF-I levels were similar. 
Duting none of rhe GH stimulation rests was the free !GF-1 level at T = o 
minutes correlated with the AUC or maximum GH concentration after 
GHRH or GHRP-6. 
Si"B!e ann stwjy: Pcgvisomant alone non significandy increased GH levels 
(Fig. 3a). Serum total !GF-I levels did nor change (Fig. 3b ), whereas serum 
free IGF-I levels decreased significandy (Fig. 3c). Duting none of the GH 
stimulation rests was the free IGF-I level at T = o minutes correlated with the 
AUC or maximum GH concentration afrer GHRH or GHRP-6. 
Cross over stu<jy vs sin3 !e ann sru<jy: Compared ro pegvisomanr &sting alone and 
&sting in combination with pegvisom.ant had similar effects on GH, total 
IGF-1 and free IGF-1. 
~ Discussion 
Three days offasting wid1 or without pegvisomant as well as pegvisomanr 
alone resulted in a decrease in serum free IGF-1 levels bur nor in rota! IGF-1 
levels. This decline in free IGF-I can be explained by several mechanisms. 
Firstly, tasting leads to a lowering in portal vein insulin conccnrrarion and 
insulin is a known stimulator ofhepatic IGF-I production (s;r4). Secondly, 
IGF-binding protein-I (IGFBPrJ levels are inversely regulated by insulin (5), 
indeed in the cross-over (fasting) study we observed a significant increase in 
IGFBPrlevels (data not shown). Finally, pegvisomant is an effective blocker 
of the GH receptor and can rhus significandy decrease hepatic IGF-1 
production (2;4). Interestingly, IGFBPr and 3 remained unchanged in the 
single arm srudy (data not shown). As we did nor measure other IGFBP' sa 
rise in one of these binding proteins cannot be excluded. 
Our data arc in accordance with Frysryk and co-workers, they roo observed 
that three days of &sting led ro a reduction in serum free- bur not rotal-
IGF-I levels with a concomitant rise in serum GH levels (15). Also, Chapman 
and co-workers observed a close temporal negative correlation between GH 
and free- bur nor rota!- IGF-1 conccnrratioru afi:cr IGF-l infusion ( r6). 
Taken together, these and other data ( 17) suggest chat circulating free IGF-l, 
bur not total IGF-I, is the major component in the negative feedback on GH 
secretion. In this respect it should be noted chat the IRMA we used to 
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determine free IGF-I measures the 'true' free IGF-I as well as the fraction of 
IGF-I which can be easily dissociated from the binding proteins. Thus 
measuring the concentration ofiGF-I that is available to the tissues ( 17). 
Our data suggest that pcgvisomant is able to mimic the cffcas of three days 
of &sting on GHRH mediated GH release. The mechanisms by which &sting 
increases GH levels is thought to be a decrease in somatostatincrgic tonus as 
well as an increase in GHRH activity [tS-zoJ. A relevant animal model in this 
respect is the transgenic grovvth retarded rat in which GH is only expressed 
in the GHRH producing hypothalamicneurones. In these animals, high hypo-
thalamic GH concentrations induce a decrease in hypothalamic GHRH out-
put with a subsequent increase in pituitary GHRH receptor expression [zt]. 
These animals are therefore highly sensitive to GHRH administration [zz]. 
We observed that pcgvisomant alone increased the sensitivity to exogenous 
GHRH. Apparently pegvisomant is unable to cross the blood-brain barrier 
and block the hypothalamic GH receptors. And thus a situation comparable 
to the one in the transgenic growth retarded rat ensues, whereby the 
increased serum GH concentration induced by pcgvisomant decreases 
hypothalamic GHRH output and subsequently increases pituitary GHRH 
receptor expression. On the basis of molecular size Thorner eta!. already 
postulated that pegvisommt docs not cross the blood-brain battier, our in 
vivo expcrintenta! data support this notion [4]. Furthermore, considering 
rhc peculiar analogy that fasting alone and pcgvisomant alone have on the 
GHRH stimulated GH release our data suggest an important role for 
increased pituitary GHRH receptor expression in the mechanism whereby 
&sting leads to an increased GHRH activity. 
Because we did not observe an additional effect of the combination of fasting 
with pegvisomant on GHRH mediated GH secretion we conclude that the 
GHRH mediated GH secretion is rmximally stimulated by &sting alone and 
GH receptor blockade alone. 
Fasting alone, but not pegvisomant alone, increased GHRP-6 mediated GH 
secretion. This observation supports previous animal data showing that the 
GHRP-6 induced activation of cells in the hypothalmtic arcuate nucleus is 
much greater in animals that have futed for 48 hours [23]. An additional 
explanation for rhe effecr offuring on the GHRP-6 induced GH release 
might be the decrease in somatostarinergic rone associated with &sting. 
Indeed, both in vitro and in vivo the GH releasing effect ofGHRP-6 can be 
attenuated by the administration of the somatostatin analogue octreotidc 
(24;25). In non-fasting conditions pcgvisomant did not result in an 
Effects ofFastins and Pesvisomant on the Growth-Honnone-Rdeasins-Honnone and Growth-Honnone-
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additional increase in GHRP-6 mediated GH secretion suggesting that the 
metabolic consequences of &sting and not the changes in GH-IGF-I axis 
induced by pcgvisomant arc of primary importance in increasing the in-vivo 
sensitivity to GHRP-6. 
The combination of three days of fasting with pegvisomant had a synergistic 
effect on the GHRP-6 mediated GH secretion. In order to stimulate GH 
release GH sccrctagogucs need an intact hypothalamopituitary system and 
GHRH antibodies virtually diminish the GH releasing capacity ofGH 
secreragogucs (z6;27). However, most interestingly arc data suggesting that 
the meclunism by which GH secretagogues lead to GH release is in parr 
mediared via an increase in GHRH release ( 28). Such an increase in GHRH 
release as a result of exogenous GHRP-6 administration in the context of d1c 
decrease in somatosratinergic tonus associated with fasting together with 
the putative upregulation of pituitary GHRH receptor expression by 
pegvisomanr could- ar leasr in part- explain the observed synergism rhat 
&sting and pegvisomant have on GHRP-6 mediated GH secretion. 
In conclusion, a period of three days of &sting as well as blockade of the GH 
receptor by pcgvisomant results in a significant decrease in serum free IGF-I 
-bur nor in total IGF-I concentrations. This decrease in free IGF-I is 
accompanied by an increase in GH concentrations. Pcgvisomant administra-
tion to non-futing subjects mimics the effects of fasting on GHRH, but not 
GHRP-6- mediated GH release. Fasting, in contrast to pegvisomant, is able 
to increase GHRP-6 mediated GH secretion. The combination of duee days of 
&sting and pegvisomant has a synergistic effect on the GHRP-6, but not on 
the GHRH mediated GH secretion. These data suggest that: 1) Circulating 
free IGF-I, and nor total IGF-I, is the major component in the negative 
feedback on GH secretion; z) Increased pituitary GHRH receptor expression 
plays a tole in the mechanism whereby &sting leads to increased GH 
concentrations; 3) In-vivo, GHRP-6 sensitivity seems to be primarily 
regulated by metabolic factors and not by clunges in GH-IGF-I axis. 
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Chapter 3·3 -Blockade of the Growth Hormone 
Receptor Unmasks Rapid Growth-Honnone-
Releasing-Pepride-6 Mediated Tissue Specific 
Insulin Resistance. 
-Abstract 
Alex F. Muller', JoopA. Janssen', Leo J. Hofland', Steven W. Lambetts', 
Martin Bidlingmaier, Christian J. Strasburger and Aatt Jan van dec Lely'. 
The roles of growth hormone (GH) and its receptor (GHR) in metabolic 
control are notyer fully understood. We studied the role ofGH and the GHR 
using the GHR antagonist pegvisomant for metabolic control in healthy 
non-obese men, in fasting and non-fasting conditions. Ten healthy subjects 
were enrolled in a double-blind, placebo controlled study on the effects of 
pegvisomant on GHRH and GH Releasing Peptide--6 (GHRP-6) induced GH 
secretion, before and after three days of &sting and under non-fasting 
conditions (n=5)· Under the condition ofGHR blockade by pegvisomanr in 
the non-fasting state, GHRP-6 ( 1 fig/kg) caused a increase in serum insulin 
(10.3 ± 2.1 versus 81.3 ± 25.4 mU/L; p<o.oor) and glucose (4-2 ± 0.3 versus 6.o 
± o.6 mmoljL; p<o.o5) concentrations. In this group, a rapid decrease in 
serum free fatty acids levels was observed. These changes were noc observed 
nnder GHR blockade during fasting, or in the absence of pegvisomant. We 
conclude that although these results were obtained from an acute study, and 
long term administration of pegvisomant could render different resulrs, that 
blockade of the GHR in the non-fasting stare induces tissue specific changes 
in insulin sensitivity, resulting in an increase in glucose- and insulin levels 
(indicating insulin resistance ofliverjmuscle), but probably aiso in an 
increase in lipogenesis (indicating normal insulin sensitivity of adipose 
tissue). These GHRP-6 mediated changes indicate char low GH bioactivity 
on the tissue level can induce changes in metabolic control, which are 
characterized by an increase in fat mass and a decrease in lean body mass. 
As a mechanism of rhese GHRP-6 mediated metabolic changes in the 
Dep:trtmcm ofinternal Medicine, Ensmus univcrsicy Medica.! Center RotterdJm, The Nccherbnds. 
Dcpli'tment ofinterrul Medicine, Med Klinik Innensc:tdt, Ludwig~M:ucim.ili:ms University, So336 
Munich, Gcrmmy. 
The Joum:tl ofClinicl Endocrinology md Meubolism zoo1; 86{:!J:59o-593· 
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non-fasting state, direct non-pituitary mediated GHRP-6 effects on the 
"gasrroentero-hepatic axis" seem probable. 
~ Introduction 
The role ofgtowth hormone (GH] and its receptor (GHR] in the metabolic 
control of man are not fully undcrscood yet. During &sring serum GH levels 
increase significantly, whereas serum total, and free insulin-like gtowth 
factor-! (IGF-1], as well as insulin levels decline ( 1-3]. Also, GH deficient 
(GHD] patients show, in parallel with acromegalic patients with high GH 
concentrations, a reduction in insulin sensitivity [4-6). In contrast to 
acromegalies, GHD patients have an increase in fur mass (FM] (>~;s;;r,8]. 
Pegvisomant is a generically manipulated GH molecule, which disables 
fimcrional dinlerization of the two GH receptor (GHR] molecules involved 
in signal transduction, due to a single mutation at the site II of the GH 
molecule. Pegvisomant is pegylated to increase serum half-life tinlc. 
Currendy, the compound is used in Phase II and III trials in the treatment 
of acromegaly (9-12]. Pegvisomant potentially can also be used in studies in 
normal individuals in order to obtain more insights in the role ofGH, its 
receptor, and its secrctagogues in metabolic control. We performed a double-
blind, placebo controlled, cross-over study, comparing the effects of placebo 
versus a single subcutaneous injccrion of So mg of pegvisomant on Growth 
Hormone Releasing Hormone (GHRH] and Growth Hormone Releasing 
Pepride-6 (GHRP-6] induced GH secretion, both before and afrer a three days 
period offasting in ten healthy young male subjects. We also repeated the 
same srudy in five of the ten subjects, but under non-fasting conditions. 
During this open-label study period, all subjects received pcgvisomant. 
- Subjects and Methods 
52 
Ten healthy male subjects 20-30 years of age (mean± SD age, 234 ± 2.7 
year; range, zo- zS) with a normal body weight (mean± SD BMI, zr.S ± 1.8 
kg/m2; range 19.7-25.8] were asked to participate. None of the subjects had a 
relevant medical history or used medication. All ten subjects participated in 
the cross-study and five of these ten subsequendy patricipated in the 
single-arm study (see below]. The study was approved by the local ethical 
committee and all subjects gave written informed consent before enrolment 
in the study. 
The study consisted of two parts: a double blind placebo controlled 
cross-over study comparing GHR blockade with placebo before and afrer 
Blockade of the Growth-Honnone Receptor Unmasks Rapid Growth-Honnone-Re!easina-Peptide-6 
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3 days of &sting (with free access to non-caloric fluids), and a single arm 
open label study in which the effect ofGHR blockade under non-listed 
conditions (continuation of subjects normal daily diet) was investigated. All 
study periods in both protocols lasted four days, during which the subjects 
were admitted to the Clinical Research Unir (CRUJ. Except for &sting study 
periods in both protocols were identical. In the &sting study, all subjects had 
ro fur from 2400 h on the day before admission until afrer rhe firsr rest. 
They were admitted to the CRU at 0730 hat which rime two indwelling 
intravenous catheters were inserted in both forearms. On days 1 and 4, a 
GHRP-6, or GHRH-test was performed between o8oo hand 0900 h. A second 
rest (GHRH, or GHRP-6test) was performed between 16oo hand 1700 h 
(exactly eight hours after the first test). Between the two testS, a standard 
light meal was served to all subjects on day 1, but nor to subjects in the 
&sting group on day 4- This light meal consisted our of two slices ofbrcad, 
wirh one unit ofbutter, one slice of cheese, one unit of fruit jelly, and one 
unit of milk (caloric content of 1764 kj). Immediately after the second GH 
stimulatory test either So mg of pegvisomant or placebo was administered 
subcutaneously. All subjects fasted from midnight day one until the end of 
the study. 
In the non-listing arms of the study, all subjects also had to &st from 2400 h 
on the day before admission until after the first test. Again, they were 
admitted to the CRU at 0730 hat which time two indwelling intravenous 
catheters were insetted in both forearms. On days 1 and 4, a GHRP-6 was 
performed between o8oo - 0900 h. A GHRH test was performed exactly eight 
hours afrer the GHRP-6 test. Between the two tesrs, a standard light meal as 
described above was served to all subjects on day 1, and on day+ 
Immediately after the GHRH rest on day one, So mg of pegvisomant was 
administered subcutaneously. A wash-out period of at least three weeks was 
chosen in between each of the admission periods for ead1 subject. To detect 
changes in concencracions over the day, blood samples for endocrine and 
metabolic parameters were taken daily at intervals of 4 hours throughout 
every srudy period of 4 days. These san1ples were used to calculate mean GH 
concentrations over the day. 
GH-srimulurion testS 
Either GHRH (Fetting, Hoofddorp, The Netherlands) or GHRP-6 (Clinalfa 
AG, Laufclingen, Switzerland) was administered as an intravenous bolus 
injection of 1 J.lg/kg body weight. Blood samples were drawn every 
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15 minutes from -15 to 120 minutes after injection. In the crossover srudy, 
tests were performed in random order. 
Stu<jy medication 
GHR-antagonist (Pegvisomanr (Soma venT"'], and placebo were supplied by 
Sensus Drug Development Corporation, Austin, Texas 787o1, USA 
Asscrys 
Samples were measured for endogenous GH in a two-site immunoassay that 
docs not cross-react with pcgvisomanr. The inter-assay Ols are 41% at 4-0 
~g/L and 3,8% at 20 ~g/L The intra-assay CVs are 34% at 0,25 ~g/L, L9% at 2,5 
~g/L, and +5% at 25 ~g(L (Med Klinik Innensradr; LMU; Munich; 
Germany] (9 J. Serum IGF-I was determined, using a commercially available 
radio-inununoassay (Biosource Europe SA, Nivdles, Belgium; intra- and 
interassay CV 5,0 and 9.6% respectively]. This IGF-I assay measures IGF-I in 
acid ethanol extracts. Free IGF-I concentrations were assessed, using a 
commercially available immunoradiomerric assay (Diagnostic System 
Laboratories, Webster, TX; intra- and intcrassay 0!10.3 and ro.7% 
respectively]. Glucose was determined with an automatic hexokinase 
method (Roche, Almere, TheN crherlands J. Insulin was assessed, by RIA 
(Medgenix Diagnostics, Brussels, Belgium; intra- and interassay CV 13.7 and 
8.o% respectively]. Free furry acids were determined with an enzymatic 
colorinrerric method (Wako chemicals GmbH, Neuss, Germany; intra- and 
interassay CV 1.1 and+r% respectively]. 
Statistical anarysis 
Means were compared with the Wilcoxons matched pairs test. All P-values 
arc two-sided, p-valucs <o.os was considered significant. Unless otherwise 
noted all results are reponed as mean± SEM. Analyses were performed, 
using Prism version 3.00 for Windows [GraphPad Software, Inc., San Diego, 
CAJ. The area under the curve was calculated by the trapezoidal rule. 
Growth honnone 
No significant differences were observed in serum GH concentrations on day 
1, expressed as area under the curve for all GH data obtained in 24 hours, 
excluding GH concentrations that were obtained during the rvvo stimulatory 
tests. On day 4, however, serum GH concentrations increased in all lasting 
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subjects, while only in the fasting, pcgvisomant pretreated subjects chis 
increase in GH was significant ( 04 ± 0.4 ng/ml on day 1 versus 2.1 ± 0.7 
ng/ml on day 4). 
Insulin 
In figure ta, serum insulin concentrations arc shown on days 1 and day 4 
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of each of the study periods. No significant clunges in serum insulin 
concentrations were observed after the administration of 1 ~g/kg ofGHRP-6. 
However, only in the presence of pegvisomant and in the non-fasting state 
was a rapid and siguificant increase in insulin levels found (day 4; 
Insulin- o8oo h versus 2400 h: 10.3 ± 2.1 versus 81.3 ± 25-4 mU(L; p<o.oo1). 
Glucose 
No significant changes were observed in glucose after GHRP-6 
administration. Again, only in the presence of pcgvisomant and in the 
non-fasting state, was a significant increase in serum glucose levels observed 
(day 4; Glucose- o8oo h versus 2400 h: 4-2 ± 0.3 versus 6.o ± o.6 mmol(L; 
p<o.o5; Figure 1 b). 
Free fa'9' acids 
Finally. only in the five non-fasting subjects, and only in the presence of 
pegvisomant was an aartc and significant decrease in serum FFA levels 
observed (day <~;FFA- o8oo h versus 16oo h: 0.33 ± 0.1 versus 0.15 ± o.o3 
mmol/L; p<o.os). Interestingly, on day 4- FFA levels did increase after GHRP-
6 administration in the futing state, regardless the presence of a GHR 
blockade (o8oo h versus 16oo h: o.89 ± o.o1 versus 1.30 ± 0.18 mmol/L; p<o.os; 
Figure rc). A decrease in serum FFA concentrations in all groups was 
observed afi:er GHRP-6 administration on day 1. 
IGF-I 
Serum total IGF-I levels did not clunge during the fasting period. However, 
we observed an increase in IGF-I levels on day 2, which was probably induced 
by the two srimularory tests on day 1 (mean IGF-I at baseline 26.6 ± 2.6 
nmol/L versus 31.9 ± 3·3 nmo/L at 16oo h on day 2).Afi:er day 2, total IGF-I 
levels began to decrease, but this decrease did not reach the level of 
siguificance on day 4- There was a slight, bur siguificant decrease during 
fasting in the presence of pegvisomant compared with the IGF-I levels in 
controls at day 4 (controls o8oo hat day 4 versus pegvisomant o8oo hat day 4: 
27.9 ± 4-0 versus 23.6 ± 4-2 nmol/L; p<o.os). Furthermore, blockade of the 
GHR did siguificandy reduce serum fi:ee IGF-I levels. This decrease was not 
further influenced during fasting (day 1 o8oo h versus day 4 o8oo h: 0.12 
± o.oz versus o.o4 ± o.oo nmolfL). 
None of these parameters did change after the administration of 1 ~g/kg of 
GHRH (data not shown). 
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'YhYii.ffi T Discussion 
In this study pegvisomanr was used to study the roles ofGH and its receptor 
in the metabolic control of the &sting status. To our surprise, we found that 
the administration of a standard dose of 1 fig/kg of GHRP-6 induced an 
acute and significant increase in serum insulin and glucose and a significant 
decrease in FFA levels in normal individuals pretreated with pegvisomant 
when not fasted. Moreover, GHRP-6 administration caused a significant 
increase in FFA in the fasting state regardless of the presence of GHR 
blockade. Why these changes were not observed afi:cr rhc administration of 
GHRH is not clear. Possibly, the cffccrs ofGHRH on metabolic processes arc 
either not impotrant or are mainly mediated by GH action, which in this 
study was reduced by pegvisomant and/ or &sting. All of these GHRP -6 
mediated changes in insulin, glucose and FFA concentrations in the 
pegvisomant pretreated, non-fasting group returned ro baseline values the 
next day (data not shown]. The decrease in serum FFA levels down to normal 
non-&sting levels on day 1 in all groups is probably caused by an 
exaggerated food intake the night before admission, as all subjecrs were 
aware of the coming &sting period, which started on day rat 2400 hr 
As they were only found in the presence of a GHR blocker, one musr 
conclude char these GHRP-6-induced changes in insulin, glucose and FFA 
levels are not modulated by the GH sysrem. These observations suggesr that 
a certain degree ofGH action in peripheral target tissues, such as the 
pancreas, adipose tissue, and liver, control these GHRP-6-depcndcnt changes 
in serum insulin, glucose and FFA levels. Apparendy there is a dclicare 
balance bcrwcen the GH- GHR system, and the GH secretagogue (GHSJ-
GHS recepror (GHS-R) system in the conrrol of the insulin- glucose- FFA 
system in healthy men, whereas blockade of the GHR unmasks tissue 
specific insulin sensitivity. This tissue specific sensitivity results in an 
increased lipogenesis (and therefore potentially in an increase in fur mass), 
whereas insulin resistance of carbohydrate metabolism might eventually 
lead to insulin rcsisrancc-rdatcd changes, as observed in type 2 diabetes 
mellitus ( 13-17]. Strikingly, the metabolic changes observed in this study 
parallel those that occur during physiological aging ( 18-zz). Interestingly, 
such changes have also been observed to a certain degree in some studies 
with some other GHS ( 23-26). The faer that GHRP-6 adminisrration induces 
these metabolic effecrs could hypothetically be explained by an upregularion 
of the GHS-R in rhe presence of pcgvisomant (27;28). Our data also provide 
some insight in the mechanisms that might underlie the observed reduced 
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insulin sensitivity in both acromegalies and in GH deficient patients, with 
respect to carbohydrate metabolism, and opposite changes in lipogenesis and 
lipolysis in GHD versus acromegaly [29-31). Apparendy the high GH 
concentrations in acromegaly augment glycolysis and lipolysis, and as a 
consequence, hyperinsulinism develops. In conditions in which GH 
signaling is lacking in peripheral tissue [e.g. GHD), however, GHS-mcdiated 
glycolysis increases, and hyperinsulinism develops, which in tum induces 
lipogenesis. Unpublished observations (A.). van der LelyJ support chis 
delicate balance between insulin and GH action, as a number of acromegalic 
patients, who were treated weekly with high dosages of So mg of 
pcgvisomant, sc, developed hypertrophy of sc adipose tissue at the injection 
site. This was a reversible phenomenon, as during the follow-up period off 
medication these changes in adipose tissue quickly resolved. 
The mechanisms responsible for the observed GHRP-6-mcdiatcd increase in 
serum glucose and insulin concentrations during GHR blockade in the 
non-furing state, arc not known. Strikingly, on day r, when all subjects were 
also in the non-fasring state, but without the presence ofGHR blockade, no 
changes in serum glucose and/or insulin concentrations were observed after 
GHRP-6 administration. Possible candidates for the observed metabolic 
changes, as cortisol, glucagon, and glucagon-like peptide-I, or somatostatin, 
all lack at least one of the characteristic metabolic reactions observed in this 
study [increases in glucose and insulin, as well in lipogenesis J. It is unlikely 
that glucocorricoids arc responsible for the increase in serum glucose and 
insulin concentrations, because on day 4, serum cortisol and ACTH levels 
decreased rapidly during the first eight hours aficr GHRP-6 administration, 
as expected on the basis of a normal diurnal pattern [data not shown). 
Although the metabolic effects of glucagon on glucose and insulin levels are 
the same as those observed after GHRP-6 administration, it has strong 
lipolytic activities as well (32-35). Glucagon-like peptide-I has both lipogenic, 
and insulinogenic aaions, but it decreases glucose levels, as it is a powerful 
glucogenic factor (36). Whether the recently discovered and first known 
endogenous ligand of the GHS receptor (37) shares the observed GHRP-6 
mediated changes metabolic parameters [and the possible subsequent 
changes in body composition) will be answered when data on the effects of 
Ghrelin administration will become available. Finally, changes in paracrine 
somatostatin aaiviry within the pancreatic islets would either increase- or 
decrease insulin secretion with opposite changes in glucose levels. Possibly, 
with this study, we have observed direct GHS-R mediated effects on 
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glycolysis and insulin secretion. 
Finally, Figure 1 dearly shows that in the &sting groups, the presence of 
pegvisomant was not siguificanrly inrportant for the changes observed in 
glucose, insulin and FFA levels. Apparently in this situation, loss ofGH 
action and/or a drop in IGF-I LeveLs, seem not to be the major pLayers in 
fasting related changes in these parameters. In the non-fasting state, 
however, and in the presence of pegvisomant, a drop in free, but not total 
IGF-I could be observed. However, we observed an increase in IGF-I levels on 
day 2 in aU subjects, which most likdy was induced by the two stimulatory 
tests on day 1. Afi:cr day 2, total IGF-I kvds began to decrease, but this 
decrease did not reach the levd of siguificance on day 4- Other studies arc 
necessary to rule out confounding cffecrs of changes in IGF-I on all noted 
findings. The question of which item (Loss ofGH action or the decrease in 
Free IGF-I concentrations) is responsible for the observed changes in glucose, 
insulin and FFA levels afi:er injection ofGHRP-6 remains to be answered. 
In concLusion, we found that under the condition of GHR blockade, GHRP-6 
has profound stimulatory effects on serum insulin, and glucose levels, which 
reflect a state of insulin resistance. These GHRP-6 induced changes onLy 
occur in the non-tasting state in the presence ofGHR blockade. In the same 
condition there is an increase in lipogenesis, which indicates tissue specific 
differential changes in insulin sensitivity that actually couLd Lead to 
undesired changes in body composition. We also condude that these 
possible effects ofGHRP-6 arc GH independent, and that in man, some 
degree ofGH action is necessary to prevent these GHRP-6-induccd 
metabolic changes. Moreover, we postuLate that direct GHS-R-mediated 
effects arc involved in the induction of the metabolic alterations, as weU as 
subsequent dranges in body composition, which arc characteristic for the 
insulin resistance syndrome. 
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Chapter 4-1 - Acute Effect ofPegvisomant on 
Cardiovascular Risk Markers in Healthy Men. 
Implications for the Pathogenesis of Atherosclerosis 
in Growth Hormone Deficiency. 
,),J, .. --R·'"'i Abstract 
A. F. Muller', F.W.G. Leebeek', JA.M.J.L. Janssen', S.W.J. Lamberts', 
L. Hofland',A.J. van der Lely'. 
Cardiovascular risk is increased in Growth hormone deficiency [ GHD ). 
GHD adults arefrequenrly abdominally obese and display features of the 
'metabolic syndrome'. Otherwise healthy abdominally obese subjecrs have 
low growth hormone (GH) levels and show features of the 'metabolic 
syndrome' as well. We investigated in healthy non-obese males the effecr of 
the GH receptor antagonist pcgvisomant in different metabolic conditions. 
This as a model for acute 'GHD' without yet the alterations in body 
composition associated with GHD. We compared the effect of pegvisomant 
with placebo before and after 3 days of lasting. In addition, we investigated 
the effect of pegvisomant under normal- i.e. fed- conditions. 
Three days of fasting as well as pegvisomant alone decreased serum free 
IGF-1 levels: 1.0±0.15 ng/mL vs 0.31±0.05 ng/mL and o.86±o.z3 ng/mL vs 
0.46±0.23 ng/mL respectively. Fasting in combination with pegvisomant also 
decreased serum free IGF-1 levels: 1.0±0.15 ng/mL vs 0.31±0.07 ng/mL. 
Treatment with pegvisomant had no additional influence on the decline of 
free IGF-1 induced by &sting. Pegvisomant alone had no influence on insulin 
sensitivity. The increase in insulin sensitivity induced by fasting was 
comparable to the increase in insulin sensitivicy induced by fasting 
combined with pegvisomant. Among serum lipid concentrations only serum 
triglycerides increased significandy as a result of pegvisomant alone: 1.0±0.2 
mmol/L vs 1.6±0.4 mmol/L. The changes in lipid concentrations induced by 
&sting alone or with pegvisom.ant were not different from that induced by 
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pcgvisomant alone. Von Willebraru! Factor antigen levels declined 
significant! y under the influence of pegvisomanr alone: 1.1±0.07 U /ml vs 
o.8±o.o6 Ujml. 
In conclusion, in different metabolic conditions the GH receptor antagonist 
pcgvisomant induces no significant acute changes in the major risk markers 
for CVD. These dara suggest that the secondary metabolic changes- e.g. 
abdominal obesity or inflammatory factors- that develop as a result of 
long standing GHD are of prinraty inrporrance in the pathogenesis of 
atherosclerosis in patients with GHD. 
~ Introduction 
Adults with growth hormone deficiency ( GHD) have an increased risk for 
cardiovascular disease (CVD) (1). Four relevant cohort studies investigating 
1197 patients on routine replacement therapy without growth hormone 
(GH) have reported a decrease in life expectancy of patients with 
hypopituitarism (z-5). The overall Relative Risk for CVD has been estimated 
at 1.47 (95% C.!.: 1.27-1.70) ( 6). Compared with age- and sex-marched normal 
subjects, patients with GHD have reduced insulin sensitivity, pro-
atherogenic hemostasis parameters and higher serum lipid concentrations. 
They thus display characteristic features of the 'metabolic syndrome' (7;8). 
Since centra! adiposity is present in GHD and because adiposity itself is 
associated with low growth hormone (GH) levels, it has been postulated that 
low GH levels play a role in rhe metabolic alterations associated with the 
'merabo!ic syndrome' (7;9-n). 
GH acts by binding ro receptors on liver and other cells. One GH molecule 
binds to two receptor molecules on the target cdl initiating dimerization of 
these receptor molecules finally resulting in the secretion oflnsulin-like 
Growth Factor-! (IGF-l) ( 12;13). Pegvisomanr is a genetically manipulated GH 
molecule, which disables functional dimerization of the rwo GH receptor 
molecules (1.4;15). In normal subjects and in patients with acromegaly, 
pegvisomanr is an effective blocker ofGH action and significantly decreases 
IGF-I concentrations ( 16;17). 
The aim of the present study was to investigate whether GH receptor 
blockade- as a model ofGHD bur wirhour the typical alterations in body 
composition- influences insulin sensitivity, hemostasis parameters and 
serum lipid concentrations in healthy non-obese males. Because &sting has 
marked effects on the GH-IGF-l axis we performed rwo studies: 1) A double 
blind placebo conrrolled cross-over study comparing the effects offasting on 
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insulin sensitivity, hemostasis parameters and serum lipid concentrations 
with and without pegvisomant; 2) A single arm study investigating the 
effect of pegvisomant during normal- fed - conditions. 
- Subjects and methods 
Study subjects 
66 
Ten healthy male subjects (mean± SD age, 23.4 ± 2.7 year; range, 20- 28) 
with a normal body weight (mean± SD BMI, 21.8 ± 1.8 kg(m2; range, 
19.7-25.8) were asked to participate. None of the subjects had a relevant 
medical history or used medication. All ten subjects participated in the 
cross-over study and five participated in the single-arm study. The local 
ethical committee approved the study and all subjects gave written informed 
consent. 
Experimental desian 
Cross-over study 
Pegvlsomant (n = 5) fasting 
Placebo (n = 5) 
fasting 
Single arm study 
Pegvisomant (n = 5) 
non~fasting 
Fiaure r: General study desian. 
The study consisted of two parts (figurer): 
Pegvisomant 
fasting 
Placebo 
fasting 
A double blind placebo controlled cross-over study comparing GHR blockade 
with placebo before and after 3 days of fasting. After an overnight fast 
subjects were admitted to the Clinical Research Unit on day rat 7-30 AM. 
Blood was drawn at 8 AM, and at 6 PM a single dose of8o mg pegvisomant 
(Sensus drug development corporation, Austin, Texas, USA) or placebo was 
administered subcutaneously (figure z). From midnight until the end of the 
study- on day 4 at 8 PM- subjects fasted (while having free access to 
non-caloric fluids). Each morning at 8 AM blood was drawn. Between the 
study periods there was a wash out period of 3 to 7 weeks. 
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Fasting period (cross over study) 
--------+--
Pegvlsomant 
blood sample l. blood sample 
t It 
blood sample 
It 
blOOd sample 
It 
Day1 Day2 Day3 Day4 
Fisure z: Overview of the stuljy periods. 
A single arm open label study in which the effect ofGHR blockade under 
non-fasted conditions [subjects received a standardized diet) was 
investigated. After an overnight fut subjects were admitted to the Clinical 
Research Unit on day 1 at no AM, at 8 AM blood was drawn and at 6PM a 
single dose of 8o mg pegvisomant was administered subcutaneously. After 
an overnight fast blood was drawn each morning at 8 AM. In chis study a 
detailed analysis ofhemostasis was performed. Hemostasis was assessed on 
day 1 and day 4 at 8 AM. 
GH, total !GF-I, free IGF-l, glucose, insulin, total cholesterol, LDL cholesterol, 
HDL cholesterol, triglycerides and lipoprotein (Lp[a)) were determined from 
all blood samples. In the single arm study fibrinogen, plasminogen, 
anriplasmin, factor VIII activity (FVIII:c), von Willebrand factor 
anrigen[vWF:ag), vWF Risrocerin cofactor [vWF:Rco) activity, vWF Collagen 
binding activity [vWF:Cba), plasminogen activator inhibitor-! (PAI-l) 
antigen, PAI-l activity, tissue plasminogen activator (t-PA) activity and t-PA 
antigen were determined at baseline and on day 4· 
Assays 
All assays were done in duplicate. Samples were measured for endogenous 
GH in a two-site immunoassay that does not cross-react with pegvisomant. 
The assay exhibits a lower detection limit of o.o2 f!g/L GH, an upper end of 
the working range of 50 )-lg/L for 25 11Lserum samples, and no cross-reaction 
with pegvisomanr up to a concentration of 5o,ooo f!g/L ( 16). The inter-assay 
coefficients of variation [ CV) arq.1% aq.o f!g/L and 3.8% at 20 f!g/L The 
intra-assay CVs are 34% at 0.25 f!g/L, 1.9% at 2.5 f!g/L,and 4-5% at 25 f!g/L 
[Med Klinik Innenstadt; LMU; Munich; Germany). Serum IGF-I was 
determined with a commercially available radioimmunoassay [Biosource 
Europe SA., Nivelles, Belgium; intra- and interassay CV 5-0 and 9.6% 
respetrively) and free !GF-I was determined with a commercially available 
immunoradiometric assay [Diagnostic System Laboratories, Webster, 1X; 
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intra- and imerassay CV 10.3 and 10.;7% respectively]. Glucose was assessed 
with a automatic hexokinase method (Roche, Almere, The Netherlands]. 
Insulin was assessed with a radioinlmunoassay (Medgenix Diagnostics, 
Brussels, Belgium; intra- and interassay CV 13.7 and 8.o% respectively]. Total 
cholesterol, LDL cholesterol, HDL cholesterol and triglycerides were assessed 
with an enzymatic colorimetric rest (Roche Diagnostics, Mannheim, 
Germany]. Lipoprotein (a] was assessed with a radioimmunoassay (Mercodia 
AB, Uppsala, Sweden]. 
Blood for determination ofhernosrasis parameters was obtained by 
venipuncrure under standardized conditions (overnight fasting, after 
15 minutes rest,. no tourniquet use) and collected in citrate (final 
concentration of o.105M], in Stabilyre® (Biopool, Umci, Sweden] for 
determination of t-PA and PAI-l activity, and in CTAD (Beckton Dickinson, 
Plymouth, UKJ for determination ofPAI-1 and t-PA antigen. Plasma was 
obtained by centrifugation at 2oooxg for 20 min at 4° C. Plasma was stored at 
-8o° C until use. FVIII:c was measured by a one stage clotting assay. vVIF:ag 
was measured by an ELISA using rabbit anti-human vWF (Dako A/S, 
Glostrop, Denmark] as primary antibody and as secondary a horseradish 
peroxidase-conjugated antibody. vWF:Rco was assayed with formalin-fixed 
platelets using the PAP-4 aggregometer (BioDataJ. vWF:Cba was assessed by 
measuring the amount of plasma vWF which binds to collagen by EIA. 
Fibrinogen was measured using the Clauss method. PA.I-1 activity was 
measured using Chromolize™ PAI-1 bio-immunoassay (BiopoolJ. 
( t-PA activity was determined using a bio-funcrional immunosorbcnt assay 
(Chromolizen<, BiopoolJ. PAI-1 antigen and t-PA antigen were measured 
using a TintElize® PAI-1 and t-PA ELISA also obtained from Biopool. 
Plasminogen and anti plasmin were determined using chromogenic 
substrates, S-2251 and S-2403 respectively, on an automated analyzer 
(Sysmex, Dade Behring, Marburg, Germany]. 
Homeostatic Mode! Assessment (HOMAJ 
Beta-cell function (%BJ and insulin sensitivity (%SJ were analyzed with the 
HOMA model (kindly provided by Dr Jonathan Levy, Diabetes Research 
Laboratories, Oxford, United Kingdom]. This is a scruccural model of 
glucose-insulin interaction, which describes the functioning of the major 
effector organs. Simultaneous assessment of the glucose and insulin 
concentrations afi:er an overnight fast in each person allows evaluation of 
the combination ofbeta-cell function and insulin sensitivity. Beta-cell 
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function and insulin sensitivity are expressed in relation to values in a 
'standard individual', in which they are each accorded the value roo%. 
The HOMA model has been validated [ r8-21]. 
Assessment ofbo<!J; composition 
Body composition was assessed with bioelectrical impedance assessment 
(Holtain Lintited, Croswell, U.KJ. Total body resistance was measured wirh a 
four-terminal portable intpedanec analyser. Measurements were made while 
the subjeCts lay comfortable on bed with the limbs abducted from the body. 
Current injector electrodes were placed just below the metacarpo-
phalangeal/mctacarpo-tarsal joint on the dorsa! side of the right handjfoot. 
Detector electrodes were placed on the posterior side of the wtisc Impedance 
was measured after a 8ooMA at sokHz current was injected. A computer 
program employing empirically derived formulas was used to calculate total 
body water (TBWJ, &t free mass (FFMJ and &t mass (FMJ. This method has 
been shown to be a reliable and valid approach for the estimation ofhuman 
body composition in healthy human beings ( 22]. 
Statistical anarysis 
An results are reported as mean± SEM. As the =inra! effect for an 
parameters studied was reached on day four a!! comparisons arc reported as 
baseline vs day four. Because aH study periods were exactly the same until 
6 PM on day 1 and in order to minimize intra-individual differences we took 
the means of the values of the fasting study periods as baseline values. 
Means from baseline aud day 4 were compared with the Wilcoxon signed 
ranks test. Correlations were calculated with Pearson correlation coefficient. 
All P-valucs arc two-sided, P-valucs <o.os were considered significant. 
Analyses were performed using SPSS version 9.0 for windows (SPSS Inc., 
Chicago, !HinoisJ. 
GH, rota!- and free IGF-I 
Cross over scu<!J;: fasting non significantly increased GH levels: 0.3±0.09 ~giL 
vs o.6±o.2 ~g/L (figure 3a]. Three days of fasting combined with pegvisomaut 
resulted in a significant increase in GH levels: o.J±o.o9 Jlg/L vs 1.8±0.5 Jlg/L 
(p "0.005]. Serum total IGF-l levels did not change; &sting: 204-6±19.2 ng/mL 
vs 214-6±30.8 ng/mL; &sting aud pegvisomanr: 204-6±19.2 ng/mL vs 
18t.5±32.3 ng/mL (figutqb). Three days of &sting as wen as fasting in 
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Fisurq:Mean values [±SEM) ofGH [A), total!GF-I [B) and free IGF-I [C): effects of 
fastina, fastins with peavisomant and peavisomant alone. 
*p<o.os, **p<o.o1 compared to baseline [Wikoxonsianed rank test). 
combination with pcgvisomant decreased serum free IGF-1 levels: r.o±o.15 
ng/ml vs 0.31±0.05 ng/ml [p" o.oos) and 1.0±0.15 ng/ml vs 0.31±0.07 ng/ml 
[p" o.oo5) respectively [figure 3c). Treatment with pegvisomant had no 
influence on the decline of free IGF-I induced by fasting. 
Sinsle ann study: pcgvisomant alone did non significandy increase GH levels: 
0.3±0.2 f!g/L vs 0-4±0.1 f!g/L [figure 3a). Serum total IGF-I levels did not 
change: 190.7±52.3 ng/ml vs 229.2±59.2 ng/ml [figure3b), whereas serum 
free IGF-I levels decreased significandy: 0.86±0.23 ng/ml vs 0-46±o.o8 ng/ml 
[p" o.o4) [figure 3c). 
Cross over sruc!Jl vs sinsle arm study: Compared to pcgvisomant alone fasting 
alone and fasting in combination with pcgvisomant had similar effects on 
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GH, total IGF-I and free IGF-l concentrations. 
Body composition 
Cross overscudy: Fat mass did not change (table 1). Fasting either wirh or 
without pegvisomant resulted in a significant decrease in fat free mass and 
coral body warcr (table 1). As the change in fat free mass was significantly 
correlared wirh rhe change in total body warer (p<o.oo1, for all srudy 
petiods J rhe change in far free mass duting &sting was most likely a result of 
the expected decline in coral body water. 
Sin81e arm study: Fat mass, fat free mass and rota! body water did nor 
change (Table 1). 
Table 1: Mean values ( ±SEM) in body composition; effects offastin8.fastin8 with 
pegvisomant and pegvisomant alone. 
Baseline Do 4 
Cross over study Single arm studv 
Fat mass (kg) 
Fat free mass (kg) 
Totll bodywater(L) 
19.0±2,6 
57.0±2.1 
41.6±1.5 
Fasting Fasting & PegV 
19.3±2.4 18.7±2.1 
53,1::1::1.9*"' 53.8±2.0* 
38.7±1.4** 39.2±1.5'0 
PegV 
20.0±3.8 
57.6±4.0 
42.1±2.9 
Note: all comparisons are pairwise. *p<o.os baseline vs day 4. **p<o.o1 baseline vs 
day 4 PeBV denotes pe8visomant. 
Beca-cdl.fimction and insulinsensitiviry 
Cross over scudy: Beta-cell fune:tion as measured with rhe HOMA model 
remained uochanged; baseline vs &sting: 139.6±140% vs 125.7±2o.6%; 
baseline vs &sting and pegvisomanc: 139.6±14,0% vs 156.0±32.5% (fignrqa). 
Fasting alone or with pegvisomant resulted in a significant increase in 
insulin sensitivity: 1664±47.7% vs 637.3±139.1% (p "o.oz) and 1664±47.7% vs 
450.1±96.4% (p "o.oo8) respee:tively (fignre 4b). The change in insulin 
sensitivity induced by &sting was not different from rhat induced by &sting 
combined wirh pegvisomant. 
Sin81e arm study: Bera-ceU fune:tion as measured wirh rhe HOMA model 
remained unchanged; baseline vs non-fasting and pegvisomant 145.8±zs% 
vs 166.5±15.2% (fignre43-). Pegvisomanrwirhout fasting had no significant 
effect on insulin sensitivity: 163. 3±78.6% vs 8z.z±8.o % ( fignre 4b ). 
Cross over scudy vs sin81e arm study: The changes in beta-ceU function and 
insulin sensitivity induced by fasting alone or with pegvisomant were not 
different from that induced by pegvisomanr wichour &sting. 
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Fisure-f Mean values (±SEM) ofberacdljimcrion [%B) (A) and insulinsensitiviry 
(%5) [B): effects of fastiJ18, fastins with pesvisomant and pesvisomant alone. 
·'p<o.os, **p<o.or compared to baseline [Wilcoxonsisned rank rest). 
Hemostasis (sinsle arm study only J 
VWF:ag changed significantly under the influence of pcgvisom.ant alone 
[table z).A similar trend was observed for FVIII:c (baseline vs three days of 
fasting: 1.7±0.1 IU/ml vs 0,9±0.2 IU/ml; p = 0.3) and vWF:activity(basclinc vs 
Table z: Mean values ( ±SEM) of coasulation and fibrinolysis parameters: effect of 
peavisoma.nt alone. 
Fibrinogen (giL) 
Plasminogen (IU/mL) 
Antiplasmin (IU/mL) 
FVIII" (IU/mL) 
vWF:ag (U/mL) 
VWF:Cba. (U/mL) 
VWF:Rco (U/mL) 
PAI-I activity (IU/mL) 
PAI·I antigen (nglmL) 
t·PA activity (IU/mL) 
t·PA antigen (ng!mL) 
*p<o.os baseline vs day 4 
Baseline 
2.3±0.2 
1.0±0.03 
0.9±0.04 
1.1±0.1 
1.1±0.07 
1.1±0.2 
1.0±0.09 
10.9±3.8 
19.3±6.0 
0.4±0.2 
5.6±0.5 
Pegvisomant 
2.4±0.3 
1.0±0.03 
1.0±0.08 
0.9±0.2 
0.8±0.06"' 
0.9±1.0 
0.8±0.1 
19.9±6.8 
22.2±5.5 
0.4±0.2 
5.9±1.2 
FVIII:c denotes Factor VIII activiry, vWF:as denotes von Willebrand Factor antis en, 
Cba denotes Co Hasen bindins acriviry, Reo denotes Risrocerin cofactor acriviry, 
PAI-l denotes PlasminosenAcrivaror Inhibitor-!, t-PA denotes Tissue Plasminosen 
Activator 
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three days of &sting: vWF:Rco r.o±o.o9 UfmL vs o.8±o.1 U/mL; p = o.o8; 
vWF:Cba 1.1±0.2 UfmL vs 0.9 ±r.o UfmL; p = o.z). Fibrinolysis parameters. 
including PAI-l and t-PA did not change during treatment (table 2). 
Lipids 
Cross over study: Fasting alone or in combination with pcgvisomant resulted 
in a significant increase in LDL: 2.2±0.2 mmol;L vs 2.9±0.3 mmol/L (p=o.o1) 
and 2.2±0.2 mmol/L vs 3-1±0.2 mmoljL (p = o.oo5); however total cholesterol 
levels did nor clrange: 3.9±0.2 mmol/L vs 4-¢0.3 mmol/L and 3.9±0.2 
mmol/L vs 4-7±0.2 mmol/L (figure 5a&b ). HDL cholesterol levels decreased as 
a result of &sting alone: 1.2±o.1 mmol/L vs 1.0±0.1 mmol/L. This decrease 
was starisricall y significant if fasting was combined with pcgvisomant 
1.2±0.1 mmol/L vs 1.1±0.07 mmol/L (p = 0.04) (figure 5c). As a result of the 
changes in total and HDL cholesterol the cholcsterol-HDL ratio rose 
significantly as a result of &sting alone and &sting in combinarion with 
pegvisomant: 3-5±0.3 vs 4-7±04 (p = o.oo5) and 3.5±0.3 vs 4-5±0.4 (p = o.oo5) 
(figure 5d). Triglycetides rose after &sting with pegvisomant: o.8±o.1 
mmol/L vs 1.1±0.2 mmol/L (p = o.o2); bur not after &sting alone: o.8±o.1 
mmol/L vs 1.o±o.o9 mmol/L (p = o.1) (figure 5d). Lipoprotein (a) increased 
significantly after fasting either without or with pegvisomant; 308.2±153.5 
U/L vs 39I.8±170.7UfL (p = o.oo8) and 308.2±153.5 U/L vs 359.3±153.0 U(L 
(p = o.oz) respecrivcly (figure 5fj. The changes in lipid levels induced by 
fasting alone were not significantly different compared to rhc changes in 
lipid levels induced by fasting combined with pegvisomant. 
Single armstu<!Jl: Total, LDL and HDL cholesterol levels did not change: 
3.9±0.3 mmol/L vs 4-2±0.3 mmol/L, 2.2±0.2 mmol/L vs 24±0.2 mmol/L and 
1.1±o.2 mmol/L vs r.o±o.o7 mmol/L rcspecrively (figure 5a-c). Pegvisomanr 
alone had no influence on tl1e total cholesterol I HDL cl1olesrerol ratio: 
4-0±0.5 vs 4-5±0.6 (figure 5d). Lipoprotein (a) did not change: 567.0±313.5 U/L 
vs 599.8±333.7 U/L (figure 5fj. The only lipid parricle that changed 
significantly was triglyceride; 1.0±0.2 mmol/L vs r.6±o4 mmol/L (p = 0.04) 
(figure 5e). 
Cross over stu<!Jl vs single arm stu<!Jl: 
The changes in lipid concentrations induced by &sting alone or with 
pegvisomant were not dil'ferent from that induced by pegvisomant without 
fasting. 
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~ Discussion 
GHD is associated with central obesity, insulin resistance, pro-atherogenic 
hemostasis parameters and elevated serum lipid concentrations (7;8;z3]. 
Treatment of GHD adults with GH attenuates central obesity and induces 
positive effects on lipid levels (24-27]. Because adiposity in otherwise healthy 
subjects is associated with low levels ofGH and treatment of middle aged 
obese males with GH resulted in a reduction of central adiposity with 
favorable effects on insulin sensitivity and lipid metabolism several authors 
have suggested an important role for GH in the dcvdopmcnt of central 
adiposity and the associated metabolic consequences (z8;29 J. 
By using the GH receptor antagonist pcgvisomant we set out to study the 
effects of'functional' GHD independently from the eventual alterations in 
body composition that are associated with long standing GHD (7 J. In our 
·study maximal pegvisomant drug levels were achieved on day four (fasting 
in combination with pegvisomant vs pcgvisomant only; 5228±745.6 ng/mL 
vs 4164±788.3 ng/ml (p=0.45, Mann Whimey U-tesrJJ, these levels were more 
than zooo-fold higher than endogenous GH levels. We used free IGF-I as a 
measure for assessing the efficacy of the GH receptor blockade (>o-32]. 
Indeed, pcgvisomant induced a significant reduction in free IGF-I resulting 
in free IGF-I levels on day four comparable to those observed in hypopituita-
rism with GHD (33]. Although, free IGF-I may nor be a marker for all local 
(paractine and/or autoctineJ GH actions the observed decline in free IGF-I 
levels can be take to indicate efficient GH receptor blockade; and, as we have 
to assume that GH exerts its actions through the GH receptor. These data, 
indeed, indicate that the administration of pcgvisomant creates a state of 
acute- functional- 'GHD'. 
Fat mass was not altered in our study; however, fat free mass decreased as a 
result of fasting. This implies that lean body mass also decreased. It should 
be noted that this decrease in fat free mass could be fully accounted for by 
the concomitant- metabolically inert- decline in total body water. 
Pegvisomant alone had no effect on insulin sensitivity, and although insulin 
sensitivity increased as a result of fasting this increase was not influenced by 
additional GH receptor blockade. From these data we conclude that acute 
impairment of the GH signaling cascade has no immediate effect on insulin 
sensitivity. In a recent study Christopher eta!. described a negative 
correlation between insulin sensitivity and IGF-I levels (34]. In our study no 
significant correlations were observed between changes in free IGF-I and 
insulin sensitivity. 
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The increased risk of cardiovascular disorders in GHD has been parriall y 
ascribed to changes in hemostasis in these patients, such as an increase in 
serum fibrinogen concentration and increased PAI-l activity [8;35). High 
fibrinogen levels arc associated with an increased incidence of stroke and 
myocardial infurction and high PAI-l activity or antigen is an independent 
risk fucror for primary and recurrent myocardial infurction [36-38). 
Johansson cr al. have shown that GHD adults have higher fibrinogen and 
PAI-l activity compared to healthy controls matched for sex, age and body 
mass index [8). In a subsequent study they observed a decrease in PAI-l afi:er 
two years ofGH therapy (35). In addition co GHD increased PAI-l activity has 
been found in abdominally obese subjects and a reduction ofPAI-I levels has 
been observed afi:cr weight loss [39 ). Probably this is due to a decrease in 
insulin resistance as a result of weight loss [4o). So it is unclear whether the 
observed changes in PAI-l activiry,PAI-1 antigen and t-PA antigen arc due to 
a direct effect ofGH itself or to changes in body composition. However, the 
fucr that in our study we observed no significant el1anges in PAI-l levels 
makes a causative role ofGH itself in the elevation ofPAI-I observed in GHD 
less likely. 
Interestingly, pegvisomant resulted in a significant decrease in vVIF:ag and a 
similar trend was seen for FVIII and vWF activity. It has long been 
recognized char there is a relationship between GH and vWF. A rise in GH is 
associated with increased vWF activity in healthy subjects [41). Our study 
rhus supports these data. In GHD subjects, Jorgensen et al. found only a 
non-significant increase in vWF:ag levels after 4 months of GH replacement 
therapy in 22 adult GHD subjects [42). Johansson er al. investigated the long 
term effects ofGH replacement therapy on hemostasis and fibrinolysis 
and found a non-significant decrease 24 months afi:cr initiation ofGH 
replacement therapy [35). However, vWF levels before starr ofGH replace-
ment were nor decreased compared to normals in this study [35). Besides 
v"WF all other hemostatic parameters including fibrinogen, plasminogen, 
antiplasmin :md t-PA remained unchanged by pcgvisomanr administration. 
Therefore GH docs not seem to play an inlporrant- direct- role in the 
regulation ofhcmostasis. The changes in coagulation factors, as observed in 
GHD arc probably caused by the metabolic changes induced by longstanding 
GHD. 
Pcgvisoma.nt alone increased serum triglyceride concentration indicating 
that GH is directly involved in the regulation of serum triglyceride. 
However, in a previous cross-sectional srudy we observed a strong 
77 
Insishts fromsrowth hormone receptor blockade 
negative correlation between free IGF-1 and triglycerides [43). Moreover, 
administration of recombinant !GF-1 has been reponed to cause a decrease in 
triglyceride levels [44). Taken together these data indicate that GH and IGF-1 
are both involved in triglyceride metabolism. Fasting alone, fasting in 
combination with pegvisomant and pegvisomant alone had similar effects 
on all the assessed lipid particles. In accordance with the previously 
described data concerning insulin sensitivity and coagulation and 
fibrinolysis factors these data also point to a primary role of changes in 
body composition and not ofGH itselfin the metabolic changes seen in 
GHD patients. 
Several authors have reponed that GH increases and IGF-1 decreases 
circulatingLp[a) [45-47). Surprisingly, pegvisomant induced no change in 
Lp[ a). It could be argued that the four day study period is too shorr to induce 
significant changes. However, four days offuring independently ofGH 
receptor blockade was able to induce significant changes in Lp[a). Apparently 
GH and IGF-1 are- at least in che shon term- only of minor importance in 
the regnlation ofLp[a). 
In conclusion, in different metabolic conditions the GH receptor antagonist 
pegvisomant induces no significant changes in the major risk markers for 
CVD. Based on these data we hypothesize that the secondary metabolic 
changes- e.g. abdominal obesity or inflammatory factors [48)- chat develop 
as a resnlt oflong standing GHD are of primary importance in the 
pathogenesis of atherosclerosis in patients with GHD. 
- Acknowledgements 
This study was supported by the Dutch Diabetes Fund [grant number: 
97-705)- The authors would like to thank all the personnel of the Clinical 
Research Unit of the Erasmus university Medical Center for their assistance 
in this study. Dr Jonathan Levy [Diabetes Research Laboratories, Radcliffe 
Infirmary, Oxford, United Kingdom) is gratefully acknowledged for 
providing the HOMA sofi:ware. We are also grateful to the personnel of the 
endocrine, hemostasis and lipid research laboratories for performing the 
assays. Pegvisomant was kindly provided by Sensus Drug development 
Company; Austin, Texas, USA. 
Acute Effect ofPegvisomant on Cardiovascular Risk Markers in Healthy Men. Implications for the 
Pathogenesis of Atherosclerosis in Growth Hormone Deficiency /Reference list 
- Reference List 
( 1) Vance ML, Mauras N. Growth hormone therapy in adults and children. 
N Eng! J Med 1999; 341(16):1206-1216. 
(z) Bares AS, Van'rHolfW, Jones PJ, Clayton RN. The effect of 
hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 
81(3):n69-1172. 
(3) Bares AS, Bullivant B, Sheppard MC, Stewart PM. Life expectancy 
following surgery for pituitary tumours. Clin Endocrinol (Ox£) 1999; 
50(3):315-319. 
(4) Bulow B,Hagmar L, MikoczyZ,Nordsrrom CH,Erfurrh EM. Increased 
cerebrovascular mortality in patients with hypopituitarism. Clin 
Endocrinol (Ox£) 1997; 46( 1)=75-81. 
(5) Rosen T, Bengtsson BA. Premature mortality due to cardiovascular 
disease in hypopituitarism. Lancet 1990; 336(8710 ):285-288. 
( 6) Erfurrh EM, Bulow B, Hagmat LE. Is vascular mortality increased in 
hypopituitarism?. Pituitary 2ooo; 3(2)=77-81. 
(7) Johannsson G,Bengtsson BA Growth hormone and the metabolic 
syndrome. J Endocrinol Invest 1999; 22(5 Suppl)=41-46. 
(8) Johansson )0, Landin K, Tengbom L, Rosen T, Bengtsson BA High 
fibrinogen and plasminogen activator inhibitor activity in growth 
hormone-deficient adults. Arreciosder Thromb 1994: 14(3 )'434-437· 
(9) Jorgensen )0, Vahl N, Fisker S, Norrelund H, Nielsen S, Dall Reral 
Somatopause and adiposity. Horm Res 1997; 48 Supplpo1-104-
( 10) Reaven GM. Banting lecture 1988. Role of insulin resistance in human 
disease. Diabetes 1988; 37( 12 ):r 595-1607. 
(n) Veldhuis JD, IranmaneshA, Ho KK, Waters MJ, Johnson ML, Lizarralde 
G. Dual defects in pulsatile growth hormone secretion and clearance 
subserve the hyposomatorropism of obesity in man. J Clin Endocrinol 
Merab 1991;72(1):51-59. 
( 12) Cunninghanr BC, Ultsch M, de Vos AM, Mulkerrin MG, Clauser KR, 
Wells )A Dimerization of the extracellular domain of the human 
growth hormone receptor by a single hormone molcrulc. Science 1991; 
254(503 3 ):821-82 5· 
(13) de VosAM, UltschM, KossiakolfM. Human growth hormone and 
extracellular domain of its receptor: crystal structure of the complex. 
Science 1992; 255(5o42):3o6-312. 
79 
So 
Insi8 hts from wowth hormone receptor blockade 
( 14] Chen WY, Wight DC, Wagner IE, Kopchick JJ. Expression of a mutated 
bovine growth hormone gene suppresses growth of transgenic mice. 
Proc Nat!Acad Sci US A 1990; 87( 13]:5061-5065. 
(15] Chen WY, Chen NY, Yunj, Wight DC, WangXZ, Wagner IE eta!. 
Amino acid residues in the third alpha-helix of growth hormone 
involved in growth promoting accivity. Mol Endoccinol1995; 9(3]: 
292-302. 
( 16] Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, 
P=oli SS et al. Growth hormone (GHJ receptor blockade with a 
PEG-modified GH (B2o36-PEG] lowers serum insulin-like growth 
fuctor-I but docs not acutely stimulate serum GH. J Clin Endoccinol 
Metab 1999; 84( 6]:zo98-2103. 
( 17] Trainer PJ, Drake WM, Katznelson L, Freda PU, Hcrman-Bonctr V, van 
der Lely AJ eta!. Treatment of acromegaly with the growth 
hormone-receptor antagonist pcgvisomant N Engl J Med zooo; 
342( 16]:1171-1177. 
( 18] Bon ora E, T argher G, Albetichc M, Bonadonna RC, Sag_,oiani F, Zen ere 
MB et al. Homeostasis model assessment closely mirrors the glucose 
clamp technique in the assessment ofinsulin sensitivity: studies in 
subjects with various degrees of glucose tolerance and insulin 
sensitivity. Diabetes Care 2ooo; 23( 1]:57-63. 
(19] Hermans MP, Levy JC, Morris Rj, Turner RC. Comparison of tests of 
beta-cell function across a range of glucose tolerance from normal to 
diabetes. Diabetes 1999; 48(9 ]:1779-1786. 
(zo] Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin 
sensitivity testS across a range of glucose tolerance from normal to 
diabetes. Diabetologia 1999; 42( 6]:678-687. 
(21] MatsudaM, DcFronzo RA. Insulin sensitivity indices obtained from 
oral glucose tolerance testing: comparison with the cuglyccmic insulin 
clamp. Diabetes Care 1999; zz(9 ]:1462-1470. 
(zz] Lukaski HC, Johnson PE, Bolonchuk WW, Lykken Gl. Assessment of 
fat-free mass using bioelectrical impedance measurements of the 
human body. Am J Clin Nutt 1985; 41(4]:810-817. 
(23] Binncrts A, Dcurenberg P, Swatt GR, Wilson JH, Lambcrts SW. Body 
composition in growth hormone-deficient adults. Am J Clin Nutt 1992; 
55(5):918-923-
Acute Effect ofPeBvisomant on Cardiovascular Risk Markers in Hen.lrlry Men. Implications for the 
Pacho8enesis of Atherosclerosis in Growth Hormone Deficienry /Reference list 
(24] Binnerrs A, Swart GR, Wilson JH, Hoogerbrugge N, PolsHA, 
Birkenhager JC et aL The effect of growth hormone administration in 
growth hormone deficient adults on bone, protein, carbohydrate and 
lipid homeostasis, as well as on body composition. Clin Endocrinol 
(Ox£] 1992; 37(1]=79-87. 
(z5] Cuneo RC,Judd S, Wallace JD, Perry-Keene D,Burger H, Lirn-Tio Set a!. 
The Australian Multicenter Trial of Growth Hormone ( GHJ Treatment 
in GH-DeficientAdults. J Clin Endocrino!Metab 1998; 83(1]:ro7-n6. 
(26] Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC eta!. 
The effects of 10 years of recombinant human growth hormone (GH] in 
adulr GH-deficient patients. J Clin Endocrinol Metab 1999; 84(8]: 
2596-2602. 
(z7] Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of rrearment 
with recombinant human growth hormone on body composition and 
metabolism in adults wirh growth hormone deficiency. N Eng! J Med 
1989; 321(z6j:r797-1803. 
(z8] Johannsson G, Marin P, Lonn L, OrrossonM, Stenlofl<, Bjomrorp Pet 
a!. Growth hormone treatment of abdominally obese men reduces 
abdominal tar mass, improves glucose and lipoprotein metabolism, and 
reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 
82(3]=727-73+ 
( 29] Nolte W, Radisch C, Amrsrrong VW, Hufuer M, von zur MA. The effect 
of recombinant human GH replacement therapy on lipoprotein( a] and 
other lipid parameters in adults with acquired GH deficiency: results of 
a double-blind and placebo-controlled trial. Eur J Endocrinol1997; 
137(5]=459-¢"6. 
(3o] Frysryk J, Hojlund K, Christensen M, Beck-Nielsen H, Orskov H. Three 
days of &sting reduces circulating free but not rota! IGF-I: a possible 
role for circulating free IGF in the feedback regulation ofGH. Growth 
hormone & IGF research 2ooo; 10:147· 
(31] Janssen JA, Lamberrs SW. Is the measurement of free IGF-I more 
indicative rhan that of roral IGF-I in the evaluation of the biological 
acriviry of the GH(IGF-I axis? J Endocrinol Invest 1999; 22(4]:313-315. 
(32] Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL et 
aL Recovery of growth hormone release from suppression by exogenous 
insulin-like growth factor I (IGF-I]: evidence for a suppressive action of 
free rather than bound IGF-!. J Clin Endocrinol Metab 1998; 83(8]: 
2836-2842. 
81 
82 
Insishrs from srowth honnone receptor blockade 
[33] JuulA, Holm K, Kastrup KW, Pedersen SA, Michaelsen KF, Scheike T et 
al Free insulin-like growth factor I serum levels in 1430 healthy 
children and adults, and its diagnostic value in patients suspected of 
growth hormone deficiency. J Clin Endoctinol Metab 1997; 8z[8]: 
2497-2502. 
[34] Christopher M, Hew Fl, Oakley M, Rantzau C, Alford F. Defects of 
insulin action and skeletal muscle glucose metabolism in growth 
hormone-deficient adults persist afi:er 24 months of recombinant 
human growth hormone therapy. J Clin Endoctinol Mecab 1998; 
83[5]:1668-1681. 
[35] Johansson JO, Landin K, Johannsson G, Tengbom L, Bengtsson BA 
Long-term treatment with growth hormone decreases plasminogen 
activator inhibitor-! and tissue plasminogen activator in growth 
hormone-deficient adults. Thromb Haen1ost 1996; 76[3]=422-428. 
[36] Hamsten A, Winlan B, de Faire U, Blomback M. Increased plasma levels 
of a rapid inhibitor of tissue plasminogen activator in young survivors 
of myocardial infuction. N Eng! J Med 1985; 313[25]:1557-1563. 
[37] HamstenA, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C et 
al. Plasminogen activator inhibitor in plasma: risk factor for recurrent 
myocardial infarction. Lancet 1987: 2[8549 ]:3-9. 
[38] Kannel WB, WolfPA, Castelli WP, D'Agosrino RB. Fibrinogen and risk of 
cardiovascular disease. The Franringhanr Study. JAMA 1987; 258[9 J: 
1183-1186. 
[39 J FolsomAR, Q_anrhieh HT, Wing RR, Jeffery RW, Stinson VL, Kullet LH 
ct al. Impact of weight loss on plasminogen activator inhibitor [PAI-1], 
factor VII, and other hen1ostaric factors in moderately overweight 
adults.Arrerioscler Thromb 1993; 13[2]:162-169. 
[40] Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K 
Plasminogen activator inhibitor-r, tissue-type plasminogen activator, 
and fibrinogen: Effect of dieting with or without exercise in overweight 
posrmenopausal women.ArreriosclerThromb VascBiol1996; 16[3]: 
381-385. 
[41] Sarji KE, Levine JH, Nair RM, Sage! J, Colwell JA Relation between 
growth hormone levels and Von Willebrand factor activiry. J Clin 
Endoctinol Metab 1977; 45[4]:853-856. 
Acute Effect ofPegvisomanr on Cardiovascular Risk Markers in Healthy Men. Implications for the 
Pathogenesis of Atherosclerosis in Growth Hormone Deficien9' /Reference list 
(42) Jorgensen JO, Pedersen SA, Ingerslev J, Moller J, Skakkebaek NE, 
Christiansen JS. Growth hormone (GH) rberapy in GH-deficient 
patients, rbe plasma factor VIII-von Willebrand factor complex, and 
capillary fragility. A double-blind, placebo-conrrolled crossover srudy. 
Scand J Clin Lab Invest 199o; 50(4)'417-420· 
(43) Janssen JA, Stolk RP, PolsHA, Grobbee DE, Lamberts SW. Serum total 
!GF-1, free IGF-1, and IGFB-1levels in an elderly population: relation to 
cardiovascular risk factors and disease. Artetioscler Thromb Vase Bioi 
1998; 18(z):277-z8z. 
(44) Froesch ER, Hussain M. Therapeutic potencial of rhlGF-1 in diabetes 
and conditions of insulin resistance. J Intern Med 1993; 234( 6):561-570. 
(45) EdenS, Wiklund 0, Oscarsson J, Rosen T, Bengrsson BA. Growth 
hormone rrcarmenr of growth hormone-deficient adults results in a 
marked increase in Lp(a) and HDL cholesterol concenrrations. 
ArteriosclerThromb 1993; 13(2):296-301. 
(46) Olivecrona H, Hilding A, Eksrrom C, Barle H, Nyberg B, Moller C et aL 
Acute and short-term effects of growth hormone on insulin-like 
growth factors and their binding proteins: serum levels and hepatic 
messenger ribonucleic acid responses in humans. J Clin Endocrine! 
Merab 1999; 84(z):553-56o. 
(47) LaronZ, Wang XL, Klinger B, SilbergeldA, Wilcken DE. Growth 
hormone increases and insulin-like growth facror-I decreases 
circulating lipoprotein( a). Eur J Endocrinol1997; 136(4):377-381. 
(48) Scsmilo G, Biller BM, Llevador J, Hayden D, Hanson G, Ritai N etaL 
Effects of growth hormone adminisrration on inflammatory and orber 
cardiovascular risk markers in men with growth hormone deficiency. 
A randomized, conrrolled clinical triaL Ann Intern Med zooo; 133(2): 
111-122. 
Chapter 4-2 - Control ofTumor Size and Disease 
Activity During Co-treatment with Octreotide and 
the Growth Hormone Receptor Antagonist 
Pegvisomant in an Acromegalic Patient 
-Abstract 
Aart Jan van der Lely', Alex F. Muller', Joop A. Jansseu', Robert J. Davis', 
Kenneth A. Zib', John A. Scarlett', Steven W. Lamberts'. 
We describe tbe case of an acromegalic subject, who was tbe first patient ever 
treated witb tbis growth hormone receptor (GHR) antagonist pegvisomant. 
Furthermore, in this particular patient progression in tumor size was 
encountered during trcarmeut witb pegvisomant. The patient described did 
benefit from co-treatment with pegvisomant and octreotidc, including 
decreased growth hormone levels, normalization of serum IGF-I 
concentrations and improvement of visual field defects. 
- Report of the case 
This 34-year old male patieut was treated by transsphenoidal selecrive 
adenomectomy for a convex GH-producing pituitary macroadenoma in 
February 1997. He had, at that time, acrive acromegaly witb &tigue, 
headaches, excessive perspiration, and joint pains. Before surgery, a 
single injection of so mg octreotide sc decreased the serum GH 
conceutration from 70 ng/mL to minimally 6 ng/mL afi:er 6hrs Serum 
prolactin (PRL) was normal, whereas secondary hypothyroidism and 
hypogonadism were present. These were subsequently treated by 
replacement therapy. The neurosurgical procedure was unsuccessful 
because 6 months afi:er operation the rumor still extended up to the optic 
chiasm, although without signs or symptoms of compression of the chiasm. 
Because of the extension dose up to the optic chiasm, it was decided not to 
treat him with radiotherapy. Because of tumor size and persistent disease 
activity, he started treatment with octreotide in sc dosages up to zoo mg 
three times daily ( t.i.d. ]. This did not result in normalization of his serum 
Dcparrmem ofimemal Medicine, Erasmus university Medical Center Rotterdam, The Netherlands, 
Sensus Drug Development Corporation: Austin; Texas; USA. 
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Dat<o 
total insulin-like growth &ctor I (IGF-I) concentrations (untreated IGF-I 
levels, 6230 nmol/L; age-adjusted upper normal level, 50 nmol/L; nadir in 
serum total IGF-I levels during rrcatmcnr with ocrreocide 200 mg sc t.i.d., 
170 nmol/ L). Therefore, it was concluded that this patient was only partially 
sensitive to ocrreotidc. 
In April1997, he received for the first time pegvisomant, as he participated as 
the fuse patient in a dose-finding study in our center. The pcgvisomanr 
dose administered was 0.3 mg/kg body weight ( 27.6 mg). A single sc 
administration of the GH receptor ( GHR) antagonist resulted in a decline in 
the total serum IGF-I level on day 3 after the injection without reaching 
norma! levels (from 233 nmol/L co 211 nmol/L). 
In July 1997, he was enrolled ina Phase ab study on the efficacy and safety of 
pegvisomant in the treatment of acromegaly. In this 6-week placcbo-
conrrollcd study, he was randomized to receive So mg pcgvisomant sconce 
weekly. A significant decrease in serum total IGF-I levels was observed (from 
305 mmol/L to 190 nmol/L), although the result was still three times the 
upper age-adjusted normal level (so nmoljL). 
Because temporarily no study drug was available, he was created again with 
octreotide sc (aoo J.lg sc r.i.d) between October 1997 and Februacy 1998. In this 
period, the nadir in total serum IGF-I concentrations in the 
pegvisomant-free period remained the same as before the first period of 
treatment with the GHRantagonist (around 150 nmol/L; sec Table 1), 
indicating that he still was only partially sensitive to octreoride treatment. 
From March 1998 onward, however, he was treated again with pcgvisomant, 
Tabler: Serum tota!IGF-I and tumor volume in cubic centimeters durins medica! 
treatment of a 34:Yr-o!d acromesa!ic patien with octreotide alone, peavisomanr alone, 
and durins coadministration with both compounds. 
Pegvlsomant dose Octreotide dose Volume (cc's) IGF-1 (nmoUL) comments 
July-97 80 mgwookly 
" 
2,6 
October·S7 
March-98 10mgC:alty 
May-98 10 mgduily 
Jvno--98 15 mgdolly 
August-98 20mg d<llly 
October-98 2Smgda:ly 
Novambor-9 30 mg dalty 
Februa:ry-99 30mgd<llfy 
Juno-99 35mgdaily 
July·W 40mg dallY 
Scptombcr-99 40mg ®ily 
Octobor-99 40 mg da~y 
Nevember-!19 40mg daily 
OACE!mbar-99 40 mgd<ldy 
January-00 40mgdarly 
March.(){) 40 mgdally 
Octrootida 200 IJ9 t.i.d. 2.9 
4.3 
4.9 
5.< 
30 mg monthly {LAR) 
30 mg monthly (I.AR) 
30 mg mol'lthly (LAR) 
30 mg monthly (lAR) 5.4 
152 
052 
045 
027 
101 
040 
025 
eo 
" 002 
o22 
003 
B2 
" 37 
37 
vlsuol flold dcfoets 
visu.:.illcld dofocts 
vjsuaJ flold defeCts 
norm.illlzation of v~!j c!lzturbancos 
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without interruptions.1n this period, pegvisomant was administered daily 
by sc injections, instead of weekly injections. A dose-responsive reduction in 
1GF-1 was observed as daily doses were gradually increased from ro mg sc to 
the maximal allowed daily dose in this study of 40 mg [see Fig. r), although 
the final serum 1GF-1 concentration was still slighdy above the upper 
limit of normal This resulted in high pegvisomant concentrations 
Fisure r: Serum GH [ns/mL), serum total1GF-1 [nmol/1), and serum pesvisomant 
[ ns/mL) concentrations in an acromesalic patient durins treatment with the GHR 
anrasonist pesvisomant in inaeasins dairy sc doses of 10-40 ms. The initiation 
cotreatmentwith octreotide lons-actins repeatable [3o ms monthly J is indicated by a 
dashed line. 
Middle, the iniral decline in serum 1GF-1 concentrations durins sc octreotide treatment 
[zoo J.lB Li.d.J before rhe start of pesvisomant theraeY is depicted as an arrow. 
300 
200 
100 
0 
Octreotido S.C. 
200 I 
• 
100 
GH (ng/ml) Octreotldo 30 mg LAR monthly 
F> 
1\ 
IGF..J (nmoUL) 
--~<1!:!1!11 ••••••••••••••••••••••••••••••••••••••• 
0 
80.000 
60.000 
40.000 
20.000 
March 1998 
Pogvlsomant levels 
(ng/ml} 
Time Jan 2000 
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[concentrations around 50,ooo ng/mL). Also, a very significant increase in 
serum GH levels was observed [maximal serum GH concentration during 
pegvisomanr therapy;z6o ng/mL). 
During September and Ocrober 1999, serum total IGF-1 concentrations 
srarted to increase again, while for the first time bitemporal visual fields 
defects were found because of a small, but significant, increase in tumor size, 
whereby the suprasellar extension was increased to the extent that 
compression of the chiasm was radiologically very likely [sec Tabler). 
These observations were accompanied by an unexplained decrease in serum 
pegvisomanr concentrations, without a change in dose. The patient's 
compliance was considered to be optimal throughout the whole period of 
observation, however [e.g. by the interpretation of drug accountability 
forms). 
In November 1999, it was decided to starr treatment with ocrreotidc, 
together with 40 mg sc pegvisomant once daily. Therefore, 30 mg 
Sandostatin LAR therapy was initiated. This resulted in a rapid 
normalization of serum total IGF-1 concentrations within 2 months 
[see Fig. r), whereas the abnormalities in the visual field completely resolved. 
Also, no further increase in tumor size on magnetic resonance imaging 
[MRIJ was observed between July 1999 and March zooo. At the sanre time, a 
striking decrease in serum GH concentrations was observed as well, down to 
levels comparable with concentrations before the start of pegvisomanr 
treatment At least up to Aprilzooo, serum IGF-1 levels remained well 
controlled with levels around 35 nmol/L. Signs and symptoms of acromegaly 
were considerably improved as well. 
~ Discussion 
The primary goal in the management of acromegaly is to reverse the effects 
ofGH hypersecretion and ro decrease rumor size as much as possible [r-3). 
The importance of "normalizing" the GH(IGF-1 axis has been demonstrated 
in two long-term studies of surgery [4) [5) in which the mortality rates of 
patients with acromegaly in whom disease control was inadequate were not 
different than those of marched controls, in contrast to the 2-4- to 48-fold 
greater mortality in patients who had persistent disease. Therefore, right 
control of the GH(IGFI axis is now considered robe an achievable and 
desired goal of therapy [ 6]. 
The reported efficacy data of the available long-acting somatostatin aualogs 
in reducing serum IGF-1 levels in acromegalic patients indicate that effective 
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control of disease activity can be achieved in two thirds of patients who are 
sensitive to somatostatin analogues [7-uJ. This leaves at least one third of 
the patients without an effective control of disease activity by medical 
intervention. To our knowledge, there arc no reports available that describe 
an increase in size of a somatotropinoma during long-term treatment with 
somatostatin analogs. 
The present case illustrates several important issues, regarding the future 
use of GHR antagonists on a large scale in the (near J future. 
Pesvisomant concentrarions 
Pegvisomanr is a genetically manipulated GH molecule that disables 
functioual dimcrization of the two GHR molecules involved in signal 
transduction, due to a single mutation at the site II of the GH molecule. 
Pegvisomant is pegylared to increase serum half-life time and to reduce the 
likelihood of antibody formation. Currently, the compound is under 
investigation in the treatment of acromegaly (13-15). Pcgvisomant blocks 
GH action, instead of inhibiting GH secretion as somatostatin analogs. This 
implies that during pegvisomant therapy GH levels arc not indicative for 
GH mediated action on IGF-I production. Although the unpegylared GHR 
antagonist docs have a higher aflinity at the sire I of the GH, compared to 
endogenous GH, one must conclude that the pegylation process has major 
influences on this affinity, because in this particular patient pegvisomant 
concentrations of as high as 5o,ooo ng/ml were not able to block GH action 
ofGH concentrations more than two hundred fold lower (250 ng/ml], 
although serum IGF-I concentrations in our patient nearly normalized when 
pegvisomant levels were around 5o,ooo ng/ml. Strikingly, in the phase II and 
III srud.ics, no dear-cut correlation between pegvisomant concentrations, 
GH levels, and efficacy data was observed (13-15]. In this particular patient, 
pegvisomant concentrations appear to be roughly correlated to the serum 
IGF-I response throughout tbe course of therapy. An unexpected finding was 
the twofold increase in serum pegvisomant concentrations, which was 
observed within one month after the initiation of ocrreotide rrcaonent, 
while pegvisomant dosages were unchanged (40 mgdailyJ. The reasons for 
this arc unclear. 
Growth honnone concentrations 
A.s has been reported before, pegvisomant induces an increase in endogenous 
serum GH concentrations in acromegalic patients. Whether this dose-
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dependant increase in serum GH concenm.rions reflects a reduction in 
receptor-mediated GH clearance, an increase in production, or modification 
of some other pathway remains unclear yet. Studies on the effect ofGHR 
blockade on the pharmacodynamics of serum GH levels arc currently being 
performed. The important observation in the present case, however, is that 
lowering serum GH concentrations by octrcotidc co-administration results 
in a synergistic decrease in serum IGF-I concentrations not achieved with 
octrcoridc or pcgvisomant administrated alone. This synergistic effect might 
be predicted, based on the mechanism of action of pegvisomant as a 
competitive GH receptor antagonist. Lowering GH levels would therefore 
make a given concentration of pcgvisomant more effective. 
Tumor size 
The present case describes the first patient in whom progression in tumor 
size was encountered during treatment with pcgvisorn.ant. No data are yet 
available that indicate whether or not the size of a GH producing rumor is 
modified by pcgvisomant. It is therefore possible that some patients with 
aggressive rumors will show an increase in rumor size during long-term 
rrearrnenr with pegvisomant alone. Therefore, patients treated with 
pegvisomant should receive routine MRI monitoring of rumor size at least 
until more data become available. The aggressiveness of the rumor in this 
particular patient might reflect a subgroup of patients in whom a close 
follow up of rumor size is mandatory with any rrearment. In this patient, 
co-treatment with octreotide and pcgvisomant did result in an 
improvcrnent in the visual field defects, while no furrhcr increase in rumor 
size was observed in between the last two MRI examinations eight months 
apart. In this period co-tteatmenr was applied in the last four months. 
~ Conclusion 
We describe a 34-year-old male acromegalic patient in whom a high dose of 
40mg pegvisomant (by sc d.ail y injections) did not complete! y normalized 
serum IGF-I concentrations. Furthermore, he is the first patient in whom 
progression in tumor size was encountered during treatment with 
pcgvisomanr, and finally he was the first patient who was successfully 
treated with long-acting octrcotide together with pegvisomant. This 
co-rreatment resulted in an adequate conrrol ofbiochemical disease activiry, 
as well as an improvement of visual field defects and a furrhcr improvement 
in signs and symptoms. 
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Chapter 5 - General Discussion and Conclusions 
The first aim of this thesis was to investigate the effects ofGHR 
blockade- by using the GHR antagonist pegvisomant- and fasting either 
alone or in combination on determinants ofGH release. The second aim was 
to investigate the effect ofGHR blockade on cardiovascular risk markers in 
healthy non-obese males. By using pegvisomant we were able to investigate 
the role of the GHR in fasting. Ten healthy non-obese subjects were 
investigated both before and afi:er a 3 day fast and again before and after a 
3 day fur in combination with pegvisomant. Secondly, five of the ten 
subjects that had already participated in the first part of our study were 
investigated again but now under non-fasting conditions. Apart from the 
fact that food intake was allowed and that in this second part of the study 
we also made a detailed assessment ofhemosrasis and fibrinolysis the study 
protocol was exactly the same as in the first- fasting- part of our study. 
In the next sections I will draw some inferences based on the findings 
presented to you in the preceding chapters. 
_-, '~''""wN<, Regulation ofGH secretion 
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Three days of &sting with or without pegvisomanr resulted in the same 
decrease in serum free IGF-I levels but not in total IGF-I levels. Concomitant 
with this decline in free IGF-I levels there was an increase in GH levels. 
Interestingly, the drop in free IGF-I was the same in both study conditions, 
but GH levels increased significantly more in rhe tasting+ pegvisomanr 
conditions, compared to fasting alone. These data are in accordance with 
Frysryk and co-workers, they too observed that three days of fasting led to a 
reduction in serum free- but not total- IGF-I levels with a concomitant rise 
in serum GH levels ( r). By using a multiple-parameter deconvolution 
method Hartman eta!. have made a detailed analysis of the mechanisms 
whereby fasting leads to an enhancement ofGH secretion (z]. They also 
found that fasting, albeit only z days in this particular study, does nor result 
in lowered serum total IGF-I concentrations. From their model these authors 
suggested that starvation-induced enhancement ofGH secretion is mediated 
by the dual effect of an increased GHRH- and a decreased somatostatin-tone. 
The data of our study suggest that free IGF-I, but not total IGF-l, is the 
major component in the negative feedback on GH secretion. As already 
stared above, there was no linear relationship between free IGF-I and GH. 
General Discussion and Conclusions /Resulation ofGH secretion 
This is dearly shown in chapter 3.1, figure 3 and chaprer p, figure 3: 
although the dedine in fi:ee-IGF-I a result of fasting was nor influenced by 
additional GHR blockade there was a dear difference in GH levds. Therefore, 
we have ro condude that factors other than free IGF-I are responsible for the 
additional increase in serum GH lcvcl.s during tasting in the presence of 
pcgvisomant. 
In order to understand why GHR blockade in addition ro fasting leads to 
higher GH levels we- and others (3)- postulate that pegvisomant does not 
cross the blood-brain-barrier. In this respect it is also important ro realize 
that the pituitary gland lies outside the blood-brain-barrier and 
pegvisomant will rhus block the pituitary GHR's leading to a reduction 
in ultra shorrloop GH auto feedback (figurer) (4). The GHR's at the 
hypothalamic level will not be blocked and therefore the hypothalamus will 
sense high GH levels that will lead to a reduction in GHRH output followed 
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expression and ultra short loop GH autofeedback. 
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by an upregulation in piruirary GHRH receptor expression. Still, at present it 
cannot be excluded that pegvisomant crosses the blood barrier. In such a 
scenario the hypothalamic GHRH neurones will sense no GH and the GHRH 
output will be increased leading to a reduction in piruirary GHRH receptors. 
But during GHR blockade alone we observed an increase instead of a decrease 
in GH release after GHRH indicating that pcgvisomant docs not enter the 
brain. Moreover, taking into account the fact that pituitary sensitivity to 
GHRH during &sting is not influenced by additional pegvisomant we 
assume that the blockade of ultra shorcloop GH auto feedback is the major 
factor responsible for the significandy higher GH levels during &sting+ 
pcgvisomant, compared to fasting alone. 
In conclusion, we have reconfirmed rhat in man free- and not total- IGF-1 
can exert negative feedback on GH secretion. By using pegvisomant in addi-
tion to &sting we have shown that other factors such as ultra shorcloop GH 
auto feedback and piruitary GHRH receptor expression have a role as well 
~ GH regulation during &sting 
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As previously mentioned, data indicate thar in &sting GH secretion is 
amplified (2;5;6). Both GHRH and somatostatin output arc thought to play a 
role in the regulation ofGH output during fasting. The recent discovery of 
ghrclin as an endogenous ligand of a GHS-R and the observation that in 
man the adtrinisttation of ghrelin strongly stimulates GH release has led to 
the hypothesis that ghrelin is another important determinant ofGH 
secretion during fasting. 
In chapter 3.1 we show that in man fasting rapidly induces an acute and 
distinct diurnal rhythm in systemic ghrelin levels that is not present in the 
fed state. Because these changes in systemic ghrelin levels arc followed by 
similar changes in serum GH levels we postulate that ghrelin is the driving 
force of the increase in GH secretion during fasting. Relevant da.ta indicate 
that -laboratory animals as well as in man- ghrclin is mainly produced in 
the stomach (7 ). Taken to gerber these data indicate that during &sting the 
piruirary is under direct gasrric control. In other words the stomach can be 
considered as a classical endocrine organ. 
In the previous serrion the role of increased pituitary GHRH receptor 
expression has already been alluded to. By performing GH stimulation tests 
with GHRH and GHRF-6 the piruirary sensitivity to these compounds and 
the influence of pegvisomant and &sting hereon has been formally 
investigated. Interestingly, &sting alone as well as pegvisomant alone 
General Discussion and Conclusions ( GH r'i)ulation durinsfastina 
resulted in a similarly increased pituitary responsiveness ro GHRH (chapter 
3.2, :figure 2]. A relevant animal model in this respect is the rransgenic 
growth retarded rat in which GH is only expressed in the GHRH producing 
hypothalamic neurones (8). In these animals, high hypothalamic GH 
concentrations induce a decrease in hypothalamic GHRH ourput with a 
subsequent increase in pituitary GHRH receptor expression. These animals 
arc therefore highly sensitive to GHRH administration (9 ). In chapter 3-2 we 
describe that pcgvisomant alone increased the sensitivity to exogenous 
GHRH. Thns our in vivo expetimental data support the notion that 
pegvisomant does not cross the blood-brain barrier (3). Apparently a 
siruation comparable to the one in the transgenic growth retarded rat 
ensues, whereby the increased serum GH concentration induced by 
pcgvisomant decreases hypothalamic GHRH ourpur and subsequently 
increases pituitary GHRH receptor expression. Furthermore, considering 
the peculiar analogy that &sting alone and pegvisomant alone have on the 
GHRH stimulated GH release our data suggest an important role for 
increased pituitary GHRH receptor expression in the mechanism whereby 
&sting leads to an increased GHRH activiry. 
Also, &sting alone- but nor pegvisomanr alone- increased pituitary 
responsiveness to GHRP-6. This observation is in line with animal data 
showing that the GHRP-6 induced activation of cells in the hypothalamic 
arcuate nucleus is much greater in animals that have fasted for 4B hours (ro). 
Before attempting to integrate the above mentioned data it should be 
mentioned that it is becoming increasingly apparent that the actions of 
GHRP's andghrelin parallel each other (n). In trying to explain rhe data the 
actions of ghrelin and GHRP' s will be considered similar. 
In conclusion the somatotroph hyperactivity of &sting can be explained at 
several levels in the regulation ofGH (figure z). Firstly, there is the 
previously described decrease in somatostatincrgic tonus as well as an 
increase in GHRH activity (z;5;6;rz). To this we add an increase in the 
production of ghrelin. Secondly, there is a concomitant effect of increased 
pituitary sensitivity to GHRP-6 (and thus ghrelin) and GHRH during 
&sting. Finally, in order to fully appreciate the meaning of these changes it 
should be noted that rhere is a well established in-vivo synergism existing 
between GHS's (and thus ghrelin) and GHRH (13). 
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- GH independent effects of ghrelin 
Chapter 3· 3 describes GH independent effects of of a standard dose of 1 f,lg/kg 
of GHRP-6 on insulin, glucose and free fatty acid levels ( 14). Under the 
condition ofGHR blockade and only under fed conditions GHRP-61ns 
profound stimulatory effects on serum insulin and glucose levels reflecting a 
state of insulin resistance at the liver and muscle level. In the same condition 
there is a decrease in FFA indicating either an increase in lipogenesis or a 
General Discussion and Conclusions I GH independent effects of ghrelin 
decrease in lipolysis. Taken together these data indicate tissue-specific 
changes in insulin sensitivity. As these GHRP-6 induced changes in insulin, 
glucose and FFA levels were only found in the presence of pcgvisomant one 
must conclude that a certain degree ofGH action in peripheral target tissues, 
such as beta-cells, adipose tissue, liver and muscle is necessary to control 
these GHRP-6 mediated changes in insulin, glucose and FFA levels. The 
potential importance of these findings lies in the fact that: r) GHRP-6 can 
be considered a synthetic analog of a naturally occurring hormone called 
ghrelin ( n); z) ghrelin is present in rhe circulation and is actively regulated 
(see chapter p); 3) the use of pegvisomant might be a model for other states 
oflow GH accion/conccnrration such as obesity, ageing, syndrome-X 
(characterized by insulin resistance, obesity and hyperreruion) and 
protracted critical illness ( 15-20 ); 4) the combination ofhyperinsulinemia 
with intact insulin sensitivity of the adiporyres will lead to an increase in fat 
mass; 5) in animal studies ghtelin also stimulates food intake ( 21-24). 
Indeed, the concept that ghrelin can lead to adiposity was subsequendy 
proven byTschop et aL (25). These authors have shown that once daily 
subcutaneous ghrelin administration co mice for 2 weeks leads to a 
significant increase in fat mass (25}. Furthermore, in this and other studies 
it was shown that ghrelin leads to an increase in food intake ( 22-25). 
What might the physiological meaning of these tissue-specific changes in 
insulin sensitivity be? In chapter 3.1 data have been presented showing that 
during fasting ghrelin levels increase. So, ghrelin might be an important 
signal of the degree of fasting to the brain and adiporyres. In this way rhe 
body can achieve a metabolic control that is also dependent the previous 
ingestion of meals and possibly also on the relative content of fat, protein 
and carboh ydrare. At least in animal studies ghrclin also stimulates food 
intake to increase the presence of sufficient nutrients. It should also be noted 
that the time course of such a GHS mediated metabolic control system is 
well equipped to fine rune the immediate active metabolic control system, 
involving glucose induced insulin release, and secondary the storage of 
nutrients as FFA in adipose tissue. 
From a potential therapeutic point of view a ghrclin antagonist might be 
used to reduce the storage ofingcsted food in adipose tissue, and &cilitatc 
glucose handling in states oflow GH action/concentration. However, in a 
recent srudy it was shown that obese subjects had lower plasma ghrelin 
concentrations than age marched lean control subjects ( z6). However, in this 
study ghrclin levels were measured in the early morning after overnight 
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fasting. Considering the data we presented in thapter 3-1 in which ghrelin 
levels were lowest in early morning these data should be interpreted with 
caunon. 
On the basis of the results described in rhis paragraph ir is also tempting to 
specuhte rhar the diurnal rhythm in insulin sensitivity is rehted to a 
ghrelin rhythm. Even more so afrer raking into account that GHS' shave 
been reponed to have an effect on sleep quality and sleep has been reponed 
to have effecrs on both glucose and insulin levels as well as on GH levels 
(27-30). 
Col!ectively, the data presented support a GH independent acute metabolic 
aerion of ghrelin. These effectS can potentially lead to an increase in body tar. 
In order to further explore the (parho )physiological significance of these 
findings further research is neccessary. 
#cwM#% Pegvisomant as a model for growth hormone deficiency 
We posruhred that we could use pegvisomant as a model of GH deficiency 
bur without the typical alterations in body composition associated with 
long-standing GH deficiency to srudy the changes in several cardiovascular 
risk markers known to phy a role in the excess cardiovascular morrality 
observed in GH deficiency (31). Chapter .p describes the result of this srudy. 
In summary, in different metabolic conditions the GH receptor antagonist 
pcgvisomant induced no significant changes in insulin sensitivity, beta-cell 
function or lipid levels including Lp(a). 
Based on these data we hypothesize that secondary metabolic changes- e.g. 
abdominal obesicy or inflammatory factors (32)- that develop as a result of 
long standing GHD and nor the hck of GH per se are of primary importance 
in the pathogenesis of atherosclerosis in patients with GHD. Considering 
the posruhred role of abdominal obesity- as opposed to GHD per se- on 
cardiovasrular risk markers it would be interesting to speculate on the effect 
ofGHD per se on ghrelin levels (33a4). 
- GHR blockade in the treatment of acromegaly 
The biochemical and clinical efficacy of pegvisomant has been shown in a 
12-week, double-blind phcebo concroUed srudy (35). In all patients on active 
treatment pegvisomant resulted in a significant dose-dependent decrease in 
serum IGF-I levels. Moreover, it was also shown that pegvisomanr reduced 
clinical symptomatology (35). 
The case we describe in chapter 42 is special on several accounts (36). He was 
General Discussion and Conclusions/ GHR blockade in che treacment of acrome&ary 
the first patient in whom progression in rumor size was encountered during 
trearmcnt with pegvisomant. Paired sets of magnetic resonance imaging sets 
from before and during treatment with pegvisomant are available for more 
the 130 patients. In patients stratified by prior treatment with or without 
radiotherapy no change in pituitary volume was observed. However, on an 
individual basis two patients demonstrated a clinically significant increase 
in tumor size. None of these two patients had received radiotherapy prior to 
pegvisomant treatment (37 ). Considering the patient described in chapter +2 
it is still unclear, whether the observed increase in size of the rumor in this 
patient has been parr of the natural history of this patricular tumor. in 
addition to growth secondary to the usc of a pegvisomant. In this patient, 
cotreatment with ocrreoti.de and pcgvisomant resulted in an improvement 
in the visual field defects, whereas no further increase in tumor size was 
observed in between the last two MRI examinations 8 months apart. In chis 
period, cotreatment was applied in the last 4 months. 
Another important observation in the ease presented in chapter +2, is that 
lowering serum GH concentrations by octreotidc coadministration results in 
a synergistic decrease in serum IGF-1 concentrations that is not achieved 
with octreotidc or pegvisomant administrated alone. This synergistic effect 
might be prcdicred, based on the mechanism of action of pegvisomanr as a 
competitive GHR antagonist (38 ). Lowering GH levels would, therefore, make 
a given concentration of pcgvisomant more effective. 
In conclusion, lowering of GH levels probably makes pegvisomanr more 
effective. In the future this might prove co be clinically important in those 
acromegalic patients that arc difficult co manage when IGF-I normalization 
is concerned. In these patients pcgvisomant should be seriously considered 
as an adjunct to rrearmcnts aimed at reducing GH secretion (dopamine 
agonists and somatostatin analogs). Moreover, long term monitoring of 
rumor size in acromegalic patients created with pegvisomant is mandatory, 
especially in patients that have not received radiotherapy. 
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In part I of the thesis we have investigated the cffccrs ofGHR blockade and 
fasting either alone or in combination on some known determinants of GH 
release. 
In chapter 3-1 we show that fasting leads to a diurnal ghrelin rhythm that 
cannot be explained by changes in insulin, glucose, or free farry acid levels. 
These thangcs in serum ghrelin levels during fasting arc followed by similar 
changes in serum GH concentrations, indicating that ghrelin is the driving 
force of increased GH secretion during fasting. By using the GH receptor 
antagonist pegvisomant we also provide indirect evidence that these changes 
in serum ghrclin levels arc not regulated by the GH receptor. Finally, we 
found that the administration of the synthetic GH secretagogue GHRP-6 
was followed by a decrease of peak ghrelin levels, but this effect could only be 
observed after several hours, suggesting that ghrclin concentrations arc 
-at least partially- regulated by a long-loop negative auto feedback control. 
In chapter 3-2 the cffecrs of fasting and pcgvisomant on basal and GHRH and 
GHRP-6 stimulated GH secretion arc described. A period of three days of 
fasting as well as blockade of the GH receptor by pegvisomant results in a 
siguificant decrease in serum free IGF-I- but not in total IGF-I 
concentrations. This decrease in free IGF-I is accompanied by an increase in 
GH concentrations. Indicating that circulating free IGF-I, and not total 
IGF-I, exerts negative feedback on GH secretion. With respect co the GHRH 
and GHRP-6 stimulated GH release we made three observations. First, 
pcgvisomant administration to non-fasting subjects mimics the effects of 
fasting on GHRH, but not GHRP-6- mediated GH release. Second, fasting 
-in contrast to pegvisomant- is able to increase GHRP-6 mediated GH 
secretion. Finally, the combination of three days of fasting and pegvisomant 
has a synergistic cffecr on the GHRP-6, but not on the GHRH mediated GH 
secretion. Based on the animal model of the transgenic growth retarded rat 
these data suggest an important role for increased pituitary GHRH receptor 
expression in the mechanism whereby fasting leads to an increased GHRH 
acrivity.!.<!sdy, these data also imply that in-vivo, GHRP-6 sensitivity seems 
to be primarily regulated by metabolic factors and not by changes in 
GH-IGF-I axis. 
From the studies on both pcpridyl and non-pepridyl GHRP' sand ghrelin it 
is known that the maximum in-vivo GH releasing capacity ofGHRP' sand 
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ghrdin is dependent on the concerted - albeic ill understood -actions of 
GHRP with GHRH. Therefore, the observed increase in ghrdin output in 
combination with the postulated pituitary GHRH receptor upregulation 
could very well explain a significant part of the increase in GH secretion. 
The last section of parr I, chapter 3· 3, describes GH independent effects of 
GHRP-6 on insulin, glucose and free tarry acid levels. Under the condition of 
GHR blockade and only under fed conditions GHRP-6 has profound stimula-
tory effects on serum insulin and glucose levels reflecting a state of insulin 
resistance at the liver and muscle level. In the same condition there is a 
decrease in FFA indicating either an increase in lipogenesis or a decrease in 
lipolysis. Taken together these chta indicate tissue-specific differential 
changes in insulin sensitiviry.As these GHRP-6induced changes in insulin, 
glucose and FFA levels were only found in the presence of pegvisomant one 
must conclude that a certain degree ofGH action in peripheral target tissues, 
such as beta-cells, adipose tissue, liver and muscle is necessary to control 
these GHRP-6 mediated changes in insnlin, glucose and FFA levels. 
Moreover, the observed hyperinsulincmia in combination 'With increased 
insulin sensitivity of the adipocytes can potentially lead roan increase in tar 
mass. 
These chta are in line with the chta from Tschop er al who have shown char 
once chily sc ghrclin administration to wild-type mice for 2 weeks leads to 
an increase in fat mass. Therefore, it might be that ghrelin acts by signaling 
the degree of &sting ro the brain and adipocytes. In this way the body can 
achieve a metabolic control that is also dependent on the previous ingestion 
of meals and- most likely- also on the relative content of tar, pro rein and 
carbohydrate. It is envisioned that in periods oflow GH bioactivity such a 
metabolic control system involves the release of ghrelin from the 
gastro-intestinal tract that induces an instant insulin resistance for 
carbohydrates (leading to increased insulin concentrations), while leaving 
sensitivity of rhe adipose tissues for insulin intact. It also stimulates food 
intake to increase the presence of sufficient nutrients. Such states oflow GH 
action/concentration include obesity, ageing, the so-called syndrome-X 
( characterized by insulin resistance, obesity and hypertension) and 
protracted critical illness with irs marked glucose intolerance and protein 
wasting, and accumulation of fat stores. 
In part II of the thesis we focus more on some pathophysiological insights 
considering GH deficiency and acromegaly that arose while using pegvisomanr. 
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In chapter 4-1 we describe the use ofGHR blockade as a model ofGH 
deficiency but without the typical alterations in body composition to study 
the changes in several cardiovascnlar risk markers known to play a role in 
the excess cardiovascular monaliry observed in GH deficiency. We observed 
that in different metabolic conditions the GH receptor antagonist 
pcgvisomant induces no significant changes in the major risk markers for 
CVD. Based on these data we hypothesize that the secondary metabolic 
changes- e.g. abdominal obesity or intlanunarory factors -that develop as a 
result oflong standing GHD and not the lack of GH per sc arc of primary 
importance in the pathogenesis of atherosclerosis in patients with GHD. 
Considering the postulated role of abdominal obesity- as opposed to GHD 
per sc- on cardiovascular risk markers it would be interesting to speculate 
on the effect of GHD per se on ghrelin levels. 
In chapter 4.2 an acromegalic patient is described in whom progression of 
pituitary rumor size was encountered during pegvisomant treatment. 
Moreover, despite a high dose of pcgvisomant serum IGF-I concentrations 
did not normalize. After the patient was treated with a combination of 
pegvisomant and octreotide the visual field defects completely resolved and 
adequate biochemical control was achieved. The important observation in 
the present case, is that lowering serum GH concentrations by ocrrcotidc co-
administration results in a synergistic decrease in serum IGF-1 
concentrations not achieved with octreotide or pcgvisomant administrated 
alone. This synergistic effect might be predicted, based on the mechanism 
of action of pegvisomant as a competitive GH receptor antagonist Lowering 
GH levels would therefore make a given concentration of pegvisomant more 
effective. 
Another item that this case teaches us that long term monitoring of tumor 
size in acromegalic patients treated with pcgvisomant is mandatory, 
especially in patients that have not received radiotherapy. 
In chapter 5 the general discussion and conclusions are presented. In this 
thesis we have investigated several aspects ofGH regulation. We provide 
indirect evidence confirming that free IGF-I- and not total IGF-I- exerts 
negative feedback on GH secretion. Moreover, by using pegvisomant we 
infer an important role for ultra shonloop GH auto feedback in the 
regulation of GH secretion. Considering the increase in GH output during 
&sting we show that the release of the newly discovered gastric hormone 
ghrelin is increased during &sting. Indirect data also indicate a role for 
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increased pituitary GHRH-receptor expression in the somatotroph 
hypcracriviry of &sting. In another study with pegvisomant we show that 
the GHS GHRP-6 has GH-independent metabolic actions that might have a 
physiological role in the storage of nuni.ents. 
Pegvisomant induces no acute changes in some cardiovascular risk markers 
known to play a role in the excess cardiovascular motta!iry observed in GHD 
patients. Therefore, we hypothesize that not the lack of GH per se bur 
secondary changes- cg. in body composition- as a result oflong standing 
GHD arc of primary importance in the pathogenesis of atherosclerosis in 
these patients. 
In our last study we describe some salient aspects from an acromegalic 
patient created with pcgvisomant. 
Chapter 6.2- Sam.envatting in het Nederlands 
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In dee! I van dit proefSchrifi: is her effect van groeihormoon receptor 
[GHR) blokkade en vasten- alleen of in combinatie- op enkele bekende 
determinanten van de groeihormoon [ GHJ afgifi:e bestudeerd. 
In hoofdstuk 3-1 wordt aangetoond dat vastcn llilleiding gcefi: tot ecn 
diurnaal ghrelin rirme dat niet door veranderingen in insulinc, glucose of 
vrijc vetzuren kan worden vcrklaard. Dczc vcrandcringcn in de ghrclin 
spicgcls tijdens vasten worden gcvolgd door soortgelijke vcrandcringcn in de 
GH concentraties in her bloed. Dit impliceerr dat ghrelin vcramwoordelijk is 
voor de verhoogde GH afgifi:e bij vasten. Door de GHR antagonist 
pcgvisomant tc gcbruikcn is op indirecte wijze aangctoond dat dezc 
vcrandcringcn in de ghrclin spicgcls niet gcrcgulccrd worden via de GHR. 
Voorts blcck dar toedicning van het symherisch GH sccretagoog [ GHS) 
"GH-releasing-peptide-6" (GHRP-6) na een aantal uren gevolgd wcrd door 
ccn vcrlaagde ghrclin pick conccnrratic. Dit suggcrecrt dar de ghrelin 
bloedspiegcls- althans ten dele- door een langzaam terngkoppelings-
mechanisme worden gcrcgulccrd. 
In hoofdstuk 3.2 worden de cffcctcn van vasten en pcgvisomant op de door 
"GH-rclcasing-hormonc" [GHRH) en GHRP-6 gestimulcerde GH afgifi:e 
bcschrcvcn. Ecn pcriodc van 3 dagcn vasten of cen periodc van 3 dagcn 
GHR blokkade lciden tot een vermindeting in de concentratie van de vrije 
insuline-achtige groeifactor-I (IGF-I) maar nicr tot een vcrmindcring in de 
conccntratic van totaal IGF-I. Dczc d.aling in vrij IGF-I gaat gcpaard met een 
gelijktijdige stijging in de GH concentratie. Dit geeft aan dat vrij IGF-I- en 
niet rotaal IGF-I- negatieve terngkoppeling uiroefem op de GH afgifi:e. Met 
bcrrckking tot de GHRH en GHRP-6 gesrimulcetde GH afgifi:e zijn cr drie 
bdangrijke bevindingcn. Ten ccrstc, pcgvisomant tocdicning aan gczondc, 
niet vastende proefpersonen imiteert het effect van vasten op de GHRH, 
maar niet op de GHRP-6 gesrimulecrdc GH afgifi:e. Ten rweede, in 
tcgenstclling tot pegvisomant is vasten in Staat om de GHRP-6 
gcstimuleerde GH afgifte verder te stimuleren. Ten derde, de combinatie 
van 3 dagen vasten en pegvisomant heefi: een synergisrisch effect op de 
GHRP-6, maar niet op de GHRH gestimuleerde GH afgifi:e. 
Naar aanleiding van het diermodel van de transgene groei gererardeerde rat 
suggereren deze gegevens dat bij de mens een belangrijke rol voor een 
tocgcnomcn cxpressie van de GHRH receptor is weggelcgd in het 
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mechanismc waardoor vasten tot ecn roegenomen GH afgifce leidt. 
Oak impliccrcn dcze bevindingcn dar de in-vivo gcvoeligheid voor GHRP-6 
vooral bepaald wordr door metaboLe &croren en nier door veranderingen in 
de GH-IGF-I as. 
Uit ccrdcrc studies met GHRP' sen met ghrclin is bckcnd dar voor ccn maxi-
maal in-vivo GH srimulerend effecr van GHRP" s de aanwezigheid van GHRH 
nood.zakclijk is. De door ons gcvonden cocgcnomcn ghrelin afgiftc tijdcns 
vasten, in combinatic met de door ons gcpostulccrdc cocgcnomen GHRH 
receptor cxpressic rijdcns vasten, kan zo de toegenomcn GH afgifte tijdcns 
vasccn- ten dele- vcrklarcn. 
In hetlaarsre hoofdsruk van dedI, hoofdstuk 3·3, worden een aanral GH 
onafhankdijke effecren van GHRP-6 op de concenrraries van insuiine, 
glucose en vrije verzuren beschreven. Tijdens GHR blokkade en aiLeen bij 
nice vastcn omsrandighedcn gccft GHRP-6 ccn stijging van de in.sulinc en 
glucose in her bloed, hergecn wijsr op insuline rcsistcnric op her nivcau van 
de Lever en spieren. Onder dezeifde condiries is er een gdijktijdige afuame 
van dc conccntratie van vrijc vctzurcn in her bloed war wijst op ccn tocnamc 
in lipogenese of een afuame in iipolyse. Er onrstaan dus weefScl-specifieke 
vcranderingcn in insulinegevocligheid. Omdat de zojuist beschrcvcn 
vcrandcringen in conccntraties van insulinc, glucose en vrijc vetzurcn allccn 
gezien werden na toediening van pcgvisomant, mocten we concludcren dar 
een bepaalde mare van GH acrivireit in de perfere weefSds- zoais beta-eel, 
verweefSel, lever en spier- noodzakdijk zijn om deze door GHRP-6 
vcroorzaakte vcrandcringen in insulinc, glucose en vrije vetzuur-spicgels re 
controlcrcn. Bovcndicn, kan dc tocgcnomcn insuline-gevoelighcid van de 
vctccllen in combinacie met de hypcrinsulinacmie tot ccn coenamc van de 
vetmassa leidcn. 
Recent hcbbcn T schOp en mcdewerkers larcn zien dar in knaagdieren 
ghrclin, gedurendc 2 wckcn 1 maal daags subcutaan toegedicnd, inderdaad 
tot ecn toenamc van de vcrmassa kan lcidcn. Mogelijk is ghrelin voor de 
herscncn en vetcdlcn een signaal dar de marc van vastcn aangcefi:. Op dczc 
wijze kan her lichaam de merabole conrrole aanpassen aan her rijdsrip- en 
mogdijk zdfS de sarnenstelling- van de laarsre maalrijd. In een dergeiijk 
sysreem zal tijdens perioden met !age GH acrivireir de afgifre van ghreiin 
uit de maag een insuline resistcntie voor carbohydraten vcroorzakcn en 
tegelijkecrijd de insulinegevoeligheid van verweefsel inracr laren. Bovendien 
srimuleett ghrelin de voedseliname. Verminderde GH acriviteit(concenrrarie 
wordt bijvoorbeeldgezien bij ovcrgewicht, veroudcring, syndroom-X 
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(gekarakrcriseerd door iruuline rcsistentie, overgewicht en hyperteruie) en 
langdurige "critical illness" gekenmerkt door glucosc-intolerantie, ciwit-
verbruik en tocname van vcrmassa. 
In dec! II van dit proefSchrifi: besteden we aandacht aan pathofjsiologisch 
inzichtcn die ontstondcn bij gebruik van pcgvisomant en GH deficicntic en 
acromegalic berrcffcn. 
In hoofdstuk 4-1 wordt her gebruik van GHR blokkade als model voor GH 
dcfi.ciCntic maar zondcr de typische veranderingen in lichaamssamcnstclling 
beschreven. In deze srudie is her effect van GHR blokkade op een aanral 
cardiovasculaire tisico kenmerken die een rol spelen bij de verhoogde 
cardiovasculairc mortaliteit van paticnten met langdurigc GH dcficiCntie 
onderzocht. Onder verschillende metabole omsrandighcden gaf GHR 
blokkadc met pegvisomant gccn vcrandcringcn in cardiovasculairc risico 
kenmerken te zien. Op grond hiervan is her waarschijnlijk zo, dar nice her 
GH rckort zelf maar de secudaire verandcringen in lichaamssamcnstclling-
met name de abdominalc obesitas- als gevolg van dit rekort een primaire 
rol spclcn in de pathogencse van athcrosclcrose bij patifuten met GH 
deficientic. 
In hoofdsruk 4-2 wordt ccn 42-jarigc patient met acromegalic beschreven, 
waarbij groei van de hypofJsc rumor met gezichtsveld uitval werd gczicn 
tijdens gebruik van pegvisomant. Gebruik van hoge doseringcn ocrreotidc 
leidde niet tot een normalisering van de IGF-I spiegel. Echter de combinatic 
van pegvisomant en octreotide resulteerde in normalisering van de 
gezichrsvelden en adequate biochernische ziekrecontrole. Dus gelijktijdig 
gcbruik van pegvisomant en octreotide heeft een synergistisch effect ten 
aanzien van de IGF-I concentratic. Deze waameming is op grond van het 
werkingsmechanisme van pegvisomant goed te begrijpen. Immers, 
pegvisomant is een competetieve GHR antagonist, een verrnindering van 
GH- door octreotide- maakt dus een gegeven concenrratie pegvisomant 
effectievcr. 
Een andere bclangtijke les uit deze ziektcgcschiedenis is dar bij gcbruik van 
pegvisomant langdurig vervolgcn van rumorvolume noodzakelijk is, met 
name bij patienten die nice behandeld zijn gcweest met radiotherapic. 
In hoofdsruk 5 worden de algemene discussie en conclusie bcschreven. In dit 
proefschrifi: zijn verschillcnde aspecten van de GH regnlatie bcschreven. We 
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lcveren indirect bewijs dar vrij -en nicr toraa!- IGF-1 vcranrwoordclijk is 
voor de ncgaricvc tcrugkoppcling op de GH afgi.frc. Door hct gcbruik van 
pegvisomant kunncn we oak ccn bclangrijkc rol voor ultra kortc ncgaticve 
tcrugkoppeling van GH op zijn cigen afgi.frc aannemclijk makcn. Ten 
aanzicn van de toegcnomen GH afgifcc bij vasten larcn we zicn dar de afgiftc 
ghrclin- ecn recent gclsolcerd hormoon dat onder andere in de maag wordt 
geproducccrd- toenccmt bij vastcn. Oak zijn cr indirccrc gcgevens die crop 
wijzen dar cen toegenomcn cxpressie van de GHRH-receptorcn cen rol 
spclcn in her mcchanisme waardoor vasten rot cen grotere GH afgiftc lcidt. 
Uit een andere srudie met pegvisomant b!ijkt dar her GHS GHRP-6 GH-
onafhankelijke metabole effectcn hecfr die een bdangrijke ro! knnnen spelen 
in de opslag van voed.ingsstoffen. 
Pcgvisomant inducecrt gccn vcrandcringcn in ccn aantal cardiovasrulaire 
risico kenmcrken waarvan bckcnd is dar zc ccn rol spelcn in de vcrhoogdc 
cardiovascul.aire morbiditeit van paticnten met GHD. Waarschijn.!ijk is 
dus nict hct tckon aan GH zclf, maar zijn secund.airc vcrandcringcn- in 
bijvoorbedd !ichaamssamensteUing- van primair be!ang in de pathogcnesc 
van athcrosclcrosc in dezc patiCntcn. 
A!s laatste besprcken we een aanta! behngrijkc aspccten van een patient met 
acromegalic die behanddd is met pcgvisomant 
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hernostase hb en her srotwi.sselings hb wil ik bedanken voot de in totaal 
5370 bcpaiingen die door jullie zijn verrichr. Met name wil ik hier noemen: 
Peter van Koetsvcld, Pier Uitterlinden, joke Zuyderwijk, Marlijn Waaijets en 
DianaMooy. 
Dt. Christian Sttasburger and dr. Martin Bidlingmaier, dear Christian and 
Martin, thank you for the 22 50 measurements you performed. It has been a 
great pleasure to collaborate with you and it would be a great pleasure to 
continue out fruitful collaboration. 
Pro£ Ezio Ghigo, dear Ezio, our colhboration has been btie£ Maybe we can 
collaborate again in the furore? 
De !eden van de promotiecommissie wil ik bedanken voor hun bereidheid 
om zitting re nemcn in de promotiecommissic. 
Het personecl van de Clinicat Research Unit, bedankt voor de zorgvuidige 
wijze waarop jullie de onderzoeksprotocollen hebben uitgewerkt. 
Het is een prestatie van formaar dat at her Hoed dat afkomstig was van de 
705 bioedafuatnes in de juiste buizen op de juiste hboratoria is terecht 
gekomen. Ik heb de samenwerking met jullie als zeer prettig en coHegiaal 
crvaren. Zondcr jullie inzet was mijn ondcrzock niet mogelijk gewccst. 
~~Mijn jongcns", beste Ton, Gijs, Shamccr, Jaco, GerarcL Eric, Alex, Martin, 
Gert-Jan en Sandy bedankt voor juHie medewcrking. 
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Mijn opleider van her ecrste uut, dr, Arie Berghour, Beste Arie jij was het die 
mij na een kone AGNIO periode in opleiding nam, door jou ben ik gevormd 
als internisr, Veel energie hebben wij gestoken in ons "post-partum 
thyreo!diris" project en on<hnks her feir dar we onze oorspronkelijke 
doelstcllingen nict hebben waargemaakt, is a! deze moeite niet voor niets 
gcweest. Ik hcb grote bcwondcring voor jou als oplcidcr en als mens. 
Be<hnkt voor alles. 
Frank en Norbert, war een eer dar jullie rnijn paranyrnfen willen zijn. 
Mijn zwagcr wil ik be<hnken voor de hulp bij her maken van de omslag. 
Beste Eric, mijn computcrhulp in bangc dagen. Ik weer het nu: het is niet 
handig om je stuurprogramma van de hardc schijf tc gooien. Bedankt ook 
voor je hulp bij het maken van die andere omslag. 
Mijn oudcrs, beste Pa en Ma, ik ben een laatbloeier en jullie hadden datal 
heel vroeg door. Jullie bclangstelling en vertrouwen ligt aan de basis van dit 
proeiSchrifr. 
Lieve Eveline, jouw steun heefi: het mogelijkgemaakr dat dit boekje nu afis. 
Ik wil je bedanken voor je begrip als ik weer eens laat thuis kwam om 
vervolgens weer hele avonden en nachren te "hobby-en" Ge had het kunnen 
weten toen je me in de bibliotheek zag zitten]. Gelukkig schenkje me ecn 
dcrde kind zodat ik mijn nachten nog steeds niet hoef te verdoen met slapen. 
Dit proefschrifi: is voor jou. 
